53 results on '"Ingrid Terreehorst"'
Search Results
2. Allergy-Test-Based Elimination Diets for the Treatment of Eosinophilic Esophagitis: A Systematic Review of Their Efficacy
- Author
-
Constantinos Pitsios, Emilia Vassilopoulou, Katerina Pantavou, Ingrid Terreehorst, Anna Nowak-Wegzryn, Antonella Cianferoni, Georgios Panagiotis Tsigkrelis, Maria Papachristodoulou, Stefanos Bonovas, and Georgios K. Nikolopoulos
- Subjects
eosinophilic esophagitis ,elimination diet ,allergens ,allergy skin tests ,skin prick tests ,specific IgE ,Medicine - Abstract
Eosinophilic esophagitis (EoE) is an immune-mediated esophageal disorder, linked with sensitization to food and airborne allergens. Dietary manipulations are proposed for the management of EoE inflammation and are often successful, confirming the etiological role of food allergens. Three different dietary approaches are widely used: the elemental, the empirical, and the allergy-test-driven approach. We performed a systematic review to assess the evidence on the association of allergens, detected by allergy tests, with clinically confirmed triggers of EoE. We systematically searched PubMed, Scopus, Embase, and the Cochrane Library, through 1 June 2021. We sought studies examining the correlation of skin-prick tests (SPT), atopy patch tests (APT), specific IgE, and serum-specific IgG4, with confirmed triggers of EoE. Data on the use of prick–prick tests were also extracted. Evidence was independently screened by two authors against predefined eligibility criteria. Risk of bias was assessed with the ROBINS-I tool. Of 52 potentially eligible studies, 16 studies fulfilling quality criteria were included. These studies used one to three different allergy tests detecting food sensitization. The positive predictive value was generally low to moderate but higher when a combination of tests was used than single-test evaluations. None of the selected studies used serum-specific IgG4. Although an extreme methodological variability was noticed in the studies, allergy-based elimination diets were estimated to be efficient in 66.7% of the cases. The efficacy of targeted elimination diets, guided by SPT, sIgE, and/or APT allergy tests, does not appear superior to empirical ones. In the future, tests using esophageal prick testing or ex vivo food antigen stimulation may prove more efficient to guide elimination diets.
- Published
- 2022
- Full Text
- View/download PDF
3. Endotyping of non-allergic, allergic and mixed rhinitis patients using a broad panel of biomarkers in nasal secretions.
- Author
-
Christine L Segboer, Wytske J Fokkens, Ingrid Terreehorst, and Cornelis M van Drunen
- Subjects
Medicine ,Science - Abstract
BACKGROUND:Endotyping chronic rhinitis has proven hardest for the subgroup of non-allergic rhinitis (NAR) patients. While IgE-related inflammation is typical for allergic rhinitis (AR), no markers have been found that can be seen to positively identify NAR. A further complication is that AR and NAR might co-exist in patients with mixed rhinitis. As previous studies have considered only a limited number of inflammatory mediators, we wanted to explore whether a wider panel of mediators could help us refine the endotyping in chronic rhinitis patients. OBJECTIVE:To endotype chronic rhinitis, and non-allergic rhinitis in particular, with help of molecular or cellular markers. METHOD:In this study we included 23 NAR patients without allergen sensitizations and with persistent rhinitis symptoms, 22 pollen sensitized rhinitis patients with seasonal symptoms, 21 mixed rhinitis patients with pollen-related symptoms and persistent symptoms outside of the pollen season, and 23 healthy controls without any symptoms. Nasal secretions were collected outside of pollen season and differences between the endotypes were assessed for a broad range of inflammatory mediators and growths factors using a multiplex ELISA. RESULTS:Although we were able to identify two new nasal secretion makers (IL-12 and HGF) that were low in mixed and AR patients versus NAR and healthy controls, the most intriguing outcome is that despite investigating 29 general inflammatory mediators and growth factors no clear profile of non-allergic or mixed rhinitis could be found. CONCLUSION:Classical inflammatory markers are not able to differentiate between non-allergic or mixed rhinitis patients and healthy controls.
- Published
- 2018
- Full Text
- View/download PDF
4. In vivo and ex vivo inflammatory responses of the esophageal mucosa to food challenge in adults with eosinophilic esophagitis
- Author
-
Maria L. Haasnoot, Mirelle T. A. Kleuskens, Alejandro Lopez‐Rincon, Mara A. P. Diks, Ingrid Terreehorst, Jaap H. Akkerdaas, Ronald van Ree, Marleen T. J. van Ampting, Johan Garssen, Frank A. Redegeld, Betty C. A. M. van Esch, and Albert J. Bredenoord
- Subjects
Immunology ,Immunology and Allergy - Published
- 2023
5. [The correct and incorrect registration of drug allergies]
- Author
-
Jarne M, van Hattem, Alf, Zwilling, and Ingrid, Terreehorst
- Subjects
Drug Hypersensitivity ,Humans ,Registries ,Netherlands - Abstract
Drug reactions are common and have a major impact on prescribing behaviour in the Netherlands. An adequate allergy registration is essential both to avoid re-exposition and to prevent unnecessary avoidance. An incomplete or incorrect registration of allergies is a threat to good medical practice, unnecessarily leading to sub-optimal treatment. National registries such as the Dutch 'LandelijkSchakelpunt' (LSP), must be easily accessible to all care providers and kept up-to-date. Healthcare providers should be properly trained in recognizing allergies as well as correct allergy registration. Additionally, healthcare providers must be given the opportunity to register as well as delete allergies from registry systems.
- Published
- 2022
6. A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus
- Author
-
Christopher Ma, Alain M. Schoepfer, Ekaterina Safroneeva, Evan S. Dellon, Albert J. Bredenoord, Mirna Chehade, Margaret H. Collins, Brian G. Feagan, Glenn T. Furuta, Sandeep K. Gupta, Ikuo Hirano, Vipul Jairath, David A. Katzka, Rish K. Pai, Marc E. Rothenberg, Alex Straumann, Seema S. Aceves, Jeffrey A. Alexander, Nicoleta C. Arva, Dan Atkins, Luc Biedermann, Carine Blanchard, Antonella Cianferoni, Constanza Ciriza de los Rios, Frederic Clayton, Carla M. Davis, Nicola de Bortoli, Jorge A. Dias, Gary W. Falk, Robert M. Genta, Gisoo Ghaffari, Nirmala Gonsalves, Thomas Greuter, Russell Hopp, Karen S. Hsu Blatman, Elizabeth T. Jensen, Doug Johnston, Amir F. Kagalwalla, Helen M. Larsson, John Leung, Hubert Louis, Joanne C. Masterson, Calies Menard-Katcher, Paul A. Menard-Katcher, Fouad J. Moawad, Amanda B. Muir, Vincent A. Mukkada, Roberto Penagini, Robert D. Pesek, Kathryn Peterson, Philip E. Putnam, Alberto Ravelli, Edoardo V. Savarino, Christoph Schlag, Philipp Schreiner, Dagmar Simon, Thomas C. Smyrk, Jonathan M. Spergel, Tiffany H. Taft, Ingrid Terreehorst, Tim Vanuytsel, Carina Venter, Mario C. Vieira, Michael Vieth, Berber Vlieg-Boerstra, Ulrike von Arnim, Marjorie M. Walker, Joshua B. Wechsler, Philip Woodland, John T. Woosley, Guang-Yu Yang, Noam Zevit, Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Ear, Nose and Throat, and AII - Inflammatory diseases
- Subjects
medicine.medical_specialty ,Consensus ,Histology ,Patient-Reported Outcomes ,Histopathology ,Outcomes ,Outcome (game theory) ,Quality of life ,Multidisciplinary approach ,Outcome Assessment, Health Care ,medicine ,Humans ,Clinical Trials ,Eosinophilic esophagitis ,Intensive care medicine ,Hepatology ,business.industry ,Gastroenterology ,Endoscopy ,Eosinophilic Esophagitis ,medicine.disease ,End Points ,Enteritis ,Quality of Life ,Symptoms ,Clinical trial ,Gastritis ,business - Abstract
The Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) collaborators are a group of more than 70 gastroenterologists, pathologists, allergists, researchers, dietitians, psychologists, and methodologists who convened in a series of in-person and virtual meetings between 2018 and 2020 with the aim of developing a core outcome set (COS) for use in therapeutic studies of pharmacologic and dietary therapies for the treatment of eosinophilic esophagitis (EoE). Given heterogeneity in reported outcomes and uncertainties regarding the most appropriate end points for use in both randomized controlled trials (RCTs) and observational studies involving EoE patients, the EoE experts launched the COREOS exercise in 2018 to standardize outcome definitions using methods established by the Core Outcome Measures in Effectiveness Trials (COMET) initiative.1,2 The COS was developed using a multiphase approach, which is summarized in Figure 1. In the first phase, systematic reviews of the literature and patient engagement surveys were conducted to identify candidate outcomes that have been previously measured and are important to patients with EoE. Next, this information was used to build a framework of different outcome domains, and working groups for each domain were assembled to review the literature for relevant end points.3–6 The relative importance of these domains was categorized in a Delphi survey as core, important, and research agenda domains, and discussed in a moderated in-person meeting on May 17, 2019 at Digestive Disease Week (San Diego, CA). In phase 3, a comprehensive list of outcome measures within each of the core domains was evaluated by the COREOS collaborators in a 2-round Delphi survey and, finally, outcomes were ratified in a virtual meeting on December 8, 2020. In this meeting summary, we highlight the major points of discussion that occurred during the development of the EoE COS.
- Published
- 2021
7. Perioperative approach of allergic patients
- Author
-
Ingrid Terreehorst, Elke M.E. Bos Drs., Fabian O. Kooij, Vincent R. van Cuilenborg, Benedikt Preckel, Jeroen Hermanides, and Markus W. Hollmann
- Subjects
Allergy ,medicine.medical_specialty ,perioperative allergy ,perioperative period ,Encephalopathy ,Perioperative Care ,Drug Hypersensitivity ,Anesthesia Procedure ,03 medical and health sciences ,Patient safety ,0302 clinical medicine ,Risk Factors ,030202 anesthesiology ,Hypersensitivity ,medicine ,Humans ,Anesthesia ,Intensive care medicine ,Anaphylaxis ,Anesthetics ,business.industry ,Anaphylactic reaction ,Perioperative ,allergy ,medicine.disease ,Anti-Bacterial Agents ,Anesthesiology and Pain Medicine ,Allergists ,Neuromuscular Blocking Agents ,business ,030217 neurology & neurosurgery - Abstract
Perioperative allergic reactions are rare, yet important complications of anesthesia. Severe, generalized allergic reactions called anaphylaxis are estimated to have a mortality of 3.5–4.8%. Adequate recognition and handling of a severe perioperative anaphylactic reaction result in better outcomes, including less hypoxic-ischemic encephalopathy and death. The diagnosis of a perioperative allergic reaction can be difficult as the list of possible culprits of a perioperative allergic reaction is extensive. Making an informed guess on the causative agent and avoiding this agent in future anesthesia procedures is undesirable and unsafe. Therefore, to ensure future patient safety, a thorough investigation following a perioperative allergic reaction is mandatory. A collaborate approach by allergists and anesthesiologists is advised. In this article, we discuss the basic approach of the allergic patient and of patients with a suspected allergy to perioperatively administered medication.
- Published
- 2021
8. Use of allergy tests to identify dietary and environmental triggers of eosinophilic esophagitis: protocol for a systematic review
- Author
-
Carmen Vidal, Georgios Panagiotis Tsigkrelis, Ingrid Terreehorst, Anna Nowak-Wegzryn, Antonella Cianferoni, Emilia Vassilopoulou, Georgios K. Nikolopoulos, Stefanos Bonovas, Maria Papachristodoulou, Constantinos Pitsios, Katerina Pantavou, Ear, Nose and Throat, and AII - Inflammatory diseases
- Subjects
Protocol (science) ,Allergy ,medicine.medical_specialty ,Allergy tests ,Eosinophilic esophagitis ,Health professionals ,Esophageal disease ,business.industry ,Subgroup analysis ,Allergens ,medicine.disease ,Diet ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Search terms ,030228 respiratory system ,medicine ,Systemic review ,Immunology and Allergy ,Treatment decision making ,business ,Intensive care medicine - Abstract
Purpose: Eosinophilic esophagitis (EoE) is a chronic immune-mediated esophageal disease. Most EoE patients have atopic comorbidities and they test positive when allergy tests are performed. Our aim is to critically assess the relation of allergens detected by allergy tests with clinically confirmed triggers of EoE. Methods: A systemic review and meta-analysis will be conducted, which will involve searching electronic databases using predetermined search terms, in order to identify relevant studies. Studies will be independently screened against predefined eligibility criteria and subgroup analysis will be used for the outcomes. Results and conclusion: The findings of this review are going to help clinicians and allied health professionals in treatment decisions.
- Published
- 2020
9. Allergy tests for the diagnosis of culprit allergens in eosinophilic esophagitis: A systematic review.
- Author
-
Pitsios, Constantinos, primary, Vassilopoulou, Emilia, additional, Pantavou, Katerina, additional, Ingrid, Terreehorst, additional, Nowak-Wegrzyn, Anna, additional, Cianferoni, Antonella, additional, Tsigkrelis, Georgios Panagiotis, additional, Papachristodoulou, Maria, additional, Bonovas, Stefanos, additional, and Nikolopoulos, Georgios K., additional
- Published
- 2022
- Full Text
- View/download PDF
10. Diagnose und Management der arzneimittelinduzierten Anaphylaxie bei Kindern - Ein EAACI-Positionspapier
- Author
-
G. du Toit, Ingrid Terreehorst, Josefina Cernadas, Claude Ponvert, Marina Atanaskovic-Markovic, Francesca Mori, Eva Rebelo Gomes, Semanur Kuyucu, Mona Kidon, J. C. Caubet, Ear, Nose and Throat, and AII - Inflammatory diseases
- Subjects
Immunology and Allergy - Published
- 2019
11. 992: ACUTE VISIBLE MUCOSAL REACTIONS OF THE ESOPHAGUS AFTER LOCAL ALLERGEN PROVOCATION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS
- Author
-
Maria Haasnoot, Mirelle Kleuskens, Ingrid Terreehorst, Jaap H. Akkerdaas, Ronald Van Ree, Frank A. Redegeld, Betty C. Van Esch, and Arjan Bredenoord
- Subjects
Hepatology ,Gastroenterology - Published
- 2022
12. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS)
- Author
-
Gisoo Ghaffari, Fouad J. Moawad, Amir F. Kagalwalla, Luc Biedermann, Constanza Ciriza de los Ríos, Carina Venter, Christopher Ma, Tim Vanuytsel, Elizabeth T. Jensen, Seema S. Aceves, Nirmala Gonsalves, Edoardo Savarino, Karen S. Hsu Blatman, Gary W. Falk, Mirna Chehade, Philip E. Putnam, Alex Straumann, Berber Vlieg-Boerstra, Vincent A. Mukkada, Robert D. Pesek, Carla M. Davis, Thomas Greuter, Amanda B. Muir, Ulrike von Arnim, Brian G. Feagan, Noam Zevit, Robert M. Genta, Tiffany H. Taft, Ekaterina Safroneeva, Rish K. Pai, Dagmar Simon, Jonathan M. Spergel, Philipp Schreiner, Calies Menard-Katcher, Helen M. Larsson, Evan S. Dellon, David A. Katzka, Marc E. Rothenberg, Sandeep K. Gupta, Antonella Cianferoni, Nicola de Bortoli, Marjorie M. Walker, Vipul Jairath, Margaret H. Collins, Frederic Clayton, Roberto Penagini, Jorge Amil Dias, Guang Yu Yang, Thomas C. Smyrk, Glenn T. Furuta, Dan Atkins, Ikuo Hirano, John Leung, John T. Woosley, Joanne C. Masterson, Alain M. Schoepfer, Joshua B. Wechsler, Philip Woodland, Albert J. Bredenoord, Alberto Ravelli, Doug Johnston, Ingrid Terreehorst, Kathryn A. Peterson, Hubert Louis, Carine Blanchard, Jeffrey A. Alexander, Mario C. Vieira, Paul Menard-Katcher, Michael Vieth, Russell J. Hopp, Nicoleta C. Arva, Christoph Schlag, Gastroenterology and Hepatology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Ear, Nose and Throat, and AII - Inflammatory diseases
- Subjects
Adult ,Male ,medicine.medical_specialty ,International Cooperation ,Immunology ,Delphi method ,610 Medicine & health ,outcomes ,clinical trials ,end points ,endoscopy ,Eosinophilic esophagitis ,histology ,histopathology ,patient-reported outcomes ,quality of life ,symptoms ,law.invention ,Randomized controlled trial ,Quality of life ,360 Social problems & social services ,law ,Humans ,Immunology and Allergy ,Medicine ,Patient Reported Outcome Measures ,Child ,Aged ,Response rate (survey) ,business.industry ,Middle Aged ,medicine.disease ,Clinical trial ,Family medicine ,Female ,Patient-reported outcome ,Observational study ,business - Abstract
BACKGROUND: End points used to determine treatment efficacy in eosinophilic esophagitis (EoE) have evolved over time. With multiple novel therapies in development for EoE, harmonization of outcomes measures will facilitate evidence synthesis and appraisal when comparing different treatments. OBJECTIVE: We sought to develop a core outcome set (COS) for controlled and observational studies of pharmacologic and diet interventions in adult and pediatric patients with EoE. METHODS: Candidate outcomes were generated from systematic literature reviews and patient engagement interviews and surveys. Consensus was established using an iterative Delphi process, with items voted on using a 9-point Likert scale and with feedback from other participants to allow score refinement. Consensus meetings were held to ratify the outcome domains of importance and the core outcome measures. Stakeholders were recruited internationally and included adult and pediatric gastroenterologists, allergists, dieticians, pathologists, psychologists, researchers, and methodologists. RESULTS: The COS consists of 4 outcome domains for controlled and observational studies: histopathology, endoscopy, patient-reported symptoms, and EoE-specific quality of life. A total of 69 stakeholders (response rate 95.8%) prioritized 42 outcomes in a 2-round Delphi process, and the final ratification meeting generated consensus on 33 outcome measures. These included measurement of the peak eosinophil count, Eosinophilic Esophagitis Histology Scoring System, Eosinophilic Esophagitis Endoscopic Reference Score, and patient-reported measures of dysphagia and quality of life. CONCLUSIONS: This interdisciplinary collaboration involving global stakeholders has produced a COS that can be applied to adult and pediatric studies of pharmacologic and diet therapies for EoE and will facilitate meaningful treatment comparisons and improve the quality of data synthesis. ispartof: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY vol:149 issue:2 pages:659-670 ispartof: location:United States status: published
- Published
- 2021
13. An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions
- Author
-
Didier G. Ebo, Ingrid Terreehorst, Susanna Voltolini, Tomaz Garcez, Peter Kopač, Jose Julio Laguna, Paul-Michel Mertes, Pascale Dewachter, Kathrin Scherer, Lene H. Garvey, Anca Mirela Chiriac, Ear, Nose and Throat, and AII - Inflammatory diseases
- Subjects
0301 basic medicine ,Hypersensitivity, Immediate ,Premedication ,Severity of Illness Index ,antibiotics ,alergija in imunologija -- diagnostika ,opioid analgesics ,0302 clinical medicine ,opioidni analgetiki ,Immunology and Allergy ,opioidi ,Incidence ,Disease Management ,preobčutljivost za zdravila -- diagnostika ,anafilaksija ,Phenotype ,Disease Susceptibility ,medicine.medical_specialty ,udc:616.097:(615.211+615.216.2) ,non-steroidal opioids ,Immunology ,anesthesia ,anti-inflammatory agents ,anestezija ,Diagnosis, Differential ,03 medical and health sciences ,allergy and immunology -- diagnosis ,antibakterijska sredstva ,anti-bacterial agents ,anesthetics ,medicine ,anaphylaxis ,Humans ,anestetiki ,nesteroidna protivnetna sredstva ,Intensive care medicine ,Perioperative Period ,Skin Tests ,drug hypersensitivity -- diagnosis ,Task force ,business.industry ,Diagnostic Tests, Routine ,Perioperative ,Immunoglobulin E ,030104 developmental biology ,030228 respiratory system ,Position paper ,Allergists ,Human medicine ,business ,antibiotiki - Abstract
Perioperative immediate hypersensitivity reactions are rare. Subsequent allergy investigation is complicated by multiple simultaneous drug exposures, the use of drugs with potent effects and the many differential diagnoses to hypersensitivity in the perioperative setting. The approach to the investigation of these complex reactions is not standardized, and it is becoming increasingly apparent that collaboration between experts in the field of allergy/immunology/dermatology and anaesthesiology is needed to provide the best possible care for these patients. The EAACI task force behind this position paper has therefore combined the expertise of allergists, immunologists and anaesthesiologists. The aims of this position paper were to provide recommendations for the investigation of immediate-type perioperative hypersensitivity reactions and to provide practical information that can assist clinicians in planning and carrying out investigations.
- Published
- 2020
14. Genetic variants associated with T cell–mediated cutaneous adverse drug reactions: a PRISMA‐compliant systematic review—An EAACI position paper
- Author
-
M. Gotua, Pascal Demoly, Marina Atanaskovic-Markovic, Knut Brockow, Munir Pirmohamed, Antonino Romano, Josefina Cernadas, Vincent Yip, Cristobalina Mayorga, Andreas J. Bircher, Abderrahim Oussalah, Jean-Christoph Roger J-P Caubet, Ingrid Terreehorst, Annick Barbaud, Jose Julio Laguna, Jean-Louis Guéant, Luciana Kase-Tanno, Miguel Blanca, Alla Nakonechna, Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Biochimie – Biologie moléculaire et Nutrition [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), University of Liverpool, Royal Liverpool and Broadgreen University Hospital NHS Trust, Institute of Translational Medicine, University of Liverpool, Instituto de Investigación Biomédica [Malaga, Spain] (IBIMA), Allergy Unit [Malaga, Spain] (National Network ARADyAL), Hospital Regional Universitario de Málaga [Spain], Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hospital de São João [Porto], Hospital Lusíadas Porto, Tbilisi State University, Technische Universität München [München] (TUM), Geneva University Hospitals and Geneva University, University Hospital Basel [Basel], University of Belgrade [Belgrade], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hospital Sírio-Libanês [São Paulo, Brazil], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Hospital Central de la Cruz Roja San Jose y Santa Adela, Clinica G.B. Morgagni (Fondazione Mediterranea), Ear, Nose and Throat, AII - Inflammatory diseases, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Salvy-Córdoba, Nathalie, Hospital Regional Universitario de Málaga = Regional University Hospital of Malaga [Spain], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Allergy Unit [Cruz Roja-Madrid], Faculté de Médecine [Nancy], Université de Lorraine (UL), Royal Liverpool University Hospital, and University of Liverpool-Royal Liverpool and Broadgreen University Hospital NHS Trust
- Subjects
0301 basic medicine ,MESH: Carbamazepine ,MESH: Drug Hypersensitivity ,Genetic variants ,T-Lymphocytes ,Dapsone ,0302 clinical medicine ,systematic review ,Abacavir ,human leukocyte antigen genes ,Immunology and Allergy ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,media_common ,ddc:618 ,[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences ,3. Good health ,[SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences ,Carbamazepine ,Pharmaceutical Preparations ,Drug Hypersensitivity Syndrome ,T cell-mediated drug hypersensitivity reactions ,T cell–mediated drug hypersensitivity reactions ,[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology ,medicine.drug ,Drug ,Nevirapine ,media_common.quotation_subject ,MESH: Pharmaceutical Preparations ,Immunology ,Human leukocyte antigen ,Drug Hypersensitivity ,03 medical and health sciences ,MESH: Drug Hypersensitivity Syndrome ,medicine ,Humans ,cutaneous adverse drug reactions ,MESH: Humans ,business.industry ,genetic variants ,Cutaneous adverse drug reactions ,[SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology ,medicine.disease ,Toxic epidermal necrolysis ,030104 developmental biology ,Human leukocyte antigen genes ,MESH: T-Lymphocytes ,030228 respiratory system ,HLA-B Antigens ,Stevens-Johnson Syndrome ,Systematic review ,MESH: HLA-B Antigens ,MESH: Stevens-Johnson Syndrome ,business ,Pharmacogenetics ,[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology - Abstract
International audience; Drug hypersensitivity reactions (DHRs) are associated with high global morbidity and mortality. Cutaneous T cell-mediated reactions classically occur more than 6 hours after drug administration and include life-threatening conditions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and hypersensitivity syndrome. Over the last 20 years, significant advances have been made in our understanding of the pathogenesis of DHRs with the identification of human leukocyte antigens as predisposing factors. This has led to the development of pharmacogenetic screening tests, such as HLA-B*57:01 in abacavir therapy, which has successfully reduced the incidence of abacavir hypersensitivity reactions. We have completed a PRISMA-compliant systematic review to identify genetic associations that have been reported in DHRs. In total, 105 studies (5554 cases and 123 548 controls) have been included in the review reporting genetic associations with carbamazepine (n = 31), other aromatic antiepileptic drugs (n = 24), abacavir (n = 11), nevirapine (n = 14), trimethoprim-sulfamethoxazole (n = 11), dapsone (n = 4), allopurinol (n = 10), and other drugs (n = 5). The most commonly reported genetic variants associated with DHRs are located in human leukocyte antigen genes and genes involved in drug metabolism pathways. Increasing our understanding of genetic variants that contribute to DHRs will allow us to improve diagnosis, develop new treatments, and predict and prevent DHRs in the future.
- Published
- 2020
15. Presumed β-Lactam Allergy and Cross-reactivity in the Operating Theater
- Author
-
Jan M. Prins, Jeroen Hermanides, Bregtje A. Lemkes, Ingrid Terreehorst, and Markus W. Hollmann
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,medicine.drug_class ,Drug allergy ,Population ,Antibiotics ,Clindamycin ,biochemical phenomena, metabolism, and nutrition ,Clostridium difficile ,medicine.disease ,Penicillin ,03 medical and health sciences ,0302 clinical medicine ,Anesthesiology and Pain Medicine ,Operating theater ,030228 respiratory system ,medicine ,Vancomycin ,030212 general & internal medicine ,Intensive care medicine ,business ,education ,medicine.drug - Abstract
A β-LACTAM allergy is the most common suspected inhospital drug allergy, with an incidence of 5 to 17% in hospitalized patients and up to 35% in the surgical population at the preoperative assessment clinic.1-5 Thus, the team in the operating theater will be confronted with these patients when perioperative antibiotic prophylaxis is needed. Frequently, the consequence of a presumed β-lactam allergy is that all β-lactam antibiotics are avoided, because of the possibility of cross-reactivity, and an alternative antibiotic, e.g., clindamycin, vancomycin, or ciprofloxacin, is prescribed.1 This may be a short-term risk-avoiding strategy during surgery, but the long-term consequences are overuse of these agents and an increase in serious hospital infections by pathogens such as Clostridium difficile and vancomycin-resistant Enterococcus, with an accompanied rise in healthcare use and costs.4 In fact, the overuse of non-β-lactam antibiotics because of reported penicillin allergy has been labeled a public health problem.6-8 In this review, we provide an evidencebased and practical approach to patients with presumed β-lactam allergy admitted to the operating theater and give guidance on the selection of alternative antibiotics based on cross-reactivity patterns.
- Published
- 2018
16. Vaccination and allergy: EAACI position paper, practical aspects
- Author
-
Knut Brockow, Lennart Nilsson, Susanne Lau, Jean-Christoph Roger J-P Caubet, Eva Netterlid, Chrysanthi Skevaki, Victoria Cardona, Johan Alm, Eva Rebelo Gomes, Jann Storsaeter, Aziz Sheikh, Giovanna Zanoni, Ingrid Terreehorst, Maria C. Jenmalm, and Jürgen Schwarze
- Subjects
medicine.medical_specialty ,Allergy ,Respiratory Medicine and Allergy ,Immunology ,adverse event ,Disease ,adjuvant ,allergy ,anaphylaxis ,vaccination ,Allergic sensitization ,03 medical and health sciences ,0302 clinical medicine ,030225 pediatrics ,Hypersensitivity ,medicine ,Humans ,Immunology and Allergy ,Child ,Preschool ,Hypersensitivity/etiology/immunology ,Adverse effect ,Intensive care medicine ,Anaphylaxis ,Lungmedicin och allergi ,Vaccines ,Vaccines/adverse effects/immunology ,ddc:618 ,Anaphylaxis/immunology ,business.industry ,Public health ,Vaccination ,Infant ,Vaccination/adverse effects ,medicine.disease ,030228 respiratory system ,Immunization ,Child, Preschool ,Adverse events ,Pediatrics, Perinatology and Child Health ,business - Abstract
Immunization is highly effective in preventing infectious diseases and therefore an indispensable public health measure. Allergic patients deserve access to the same publicly recommended immunizations as nonallergic patients unless risks associated with vaccination outweigh the gains. Whereas the number of reported possible allergic reactions to vaccines is high, confirmed vaccine-triggered allergic reactions are rare. Anaphylaxis following vaccination is rare, affecting less than 1/100,000, but can occur in any patient. Some patient groups, notably those with a previous allergic reaction to a vaccine or its components, are at heightened risk of allergic reaction and require special precautions. Allergic reactions, however, may occur in patients without known risk factors and cannot be predicted by currently available tools. Unwarranted fear and uncertainty can result in incomplete vaccination coverage for children and adults with or without allergy. In addition to concerns about an allergic reaction to the vaccine itself, there is fear that routine childhood immunization may promote the development of allergic sensitization and disease. Thus, although there is no evidence that routine childhood immunization increases the risk of allergy development, such risks need to be discussed. This article is protected by copyright. All rights reserved.
- Published
- 2017
17. Guidelines on eosinophilic esophagitis: evidence‐based statements and recommendations for diagnosis and management in children and adults
- Author
-
Joaquín Rodríguez-Sánchez, Alex Straumann, Jukka Ronkainen, Alberto Ravelli, Stephen Attwood, Alain M. Schoepfer, Stephan Miehlke, Alfredo J. Lucendo, Jesús González-Cervera, Jorge Amil Dias, Javier Molina-Infante, Ulrike von Arnim, Christian Bussmann, Ingrid Terreehorst, Cecilio Santander, Helen Larsson, Ángel Arias, Mogens Bove, Alexandra Papadopoulou, Martin Storr, Albert J. Bredenoord, University of Zurich, and Lucendo, Alfredo J
- Subjects
medicine.medical_specialty ,Pediatrics ,Evidence-based practice ,Manometry ,Food impaction ,evidence-based practice ,610 Medicine & health ,03 medical and health sciences ,0302 clinical medicine ,Epidemiology ,medicine ,Humans ,2715 Gastroenterology ,guidelines ,Eosinophilic esophagitis ,Grading (education) ,Review Articles ,business.industry ,Gastroenterology ,Reference Standards ,medicine.disease ,Dysphagia ,Esophageal Achalasia ,10219 Clinic for Gastroenterology and Hepatology ,Oncology ,030220 oncology & carcinogenesis ,Family medicine ,2730 Oncology ,030211 gastroenterology & hepatology ,Esophagoscopy ,Allergists ,consensus development conferences ,medicine.symptom ,business ,Esophagitis - Abstract
Eosinophilic esophagitis (EoE) is one of the most prevalent esophageal diseases and the leading cause of dysphagia and food impaction in children and young adults. This underlines the importance of optimizing diagnosys and treatment of the condition, especially after the increasing amount of knowledge on EoE recently published. Therefore, the UEG, EAACI ESPGHAN, and EUREOS deemed it necessary to update the current guidelines regarding conceptual and epidemiological aspects, diagnosis, and treatment of EoE. General methodology according to the Appraisal of Guidelines for Research and Evaluation (AGREE) II and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used in order to comply with current standards of evidence assessment in formulation of recommendations. An extensive literature search was conducted up to August 2015 and periodically updated. The working group consisted of gastroenterologists, allergists, pediatricians, otolaryngologists, pathologists, and epidemiologists. Systematic evidence-based reviews were performed based upon relevant clinical questions with respect to patient-important outcomes. The guidelines include updated concept of EoE, evaluated information on disease epidemiology, risk factors, associated conditions, and natural history of EoE in children and adults. Diagnostic conditions and criteria, the yield of diagnostic and disease monitoring procedures, and evidence-based statements and recommendation on the utility of the several treatment options for patients EoE are provided. Recommendations on how to choose and implement treatment and long-term management are provided based on expert opinion and best clinical practice. Evidence-based recommendations for EoE diagnosis, treatment modalities, and patients' follow up are proposed in the guideline
- Published
- 2017
18. Awake intravenous provocation with small doses of neuromuscular blocking agent in patients with suspected allergy: experiences from the Dutch Perioperative Allergy Centre
- Author
-
Jeroen Hermanides, Fabian O. Kooij, Ingrid Terreehorst, Markus W. Hollmann, Elke M. E. Bos, Vincent R. van Cuilenborg, Anesthesiology, ACS - Diabetes & metabolism, AGEM - Endocrinology, metabolism and nutrition, APH - Quality of Care, Graduate School, AII - Inflammatory diseases, Ear, Nose and Throat, ACS - Heart failure & arrhythmias, and ACS - Microcirculation
- Subjects
Allergy ,Dose-Response Relationship, Drug ,business.industry ,Blocking (radio) ,Provocation test ,Perioperative ,medicine.disease ,Drug Hypersensitivity ,Anesthesiology and Pain Medicine ,Anesthesia ,Injections, Intravenous ,Medicine ,Humans ,In patient ,Neuromuscular Blocking Agents ,Wakefulness ,business ,Netherlands - Published
- 2019
19. Diagnosis and management of drug-induced anaphylaxis in children: An EAACI position paper
- Author
-
Claude Ponvert, Marina Atanaskovic-Markovic, Josefina Cernadas, Ingrid Terreehorst, Mona Kidon, Jean-Christoph Roger J-P Caubet, Eva Rebelo Gomes, Semanur Kuyucu, George Du Toit, and Francesca Mori
- Subjects
Drug ,medicine.medical_specialty ,media_common.quotation_subject ,Immunology ,Provocation test ,Drug allergy ,Immunoglobulin E ,Diagnosis, Differential ,Drug Hypersensitivity ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,medicine ,Immunology and Allergy ,Humans ,030212 general & internal medicine ,Medical prescription ,Intensive care medicine ,Child ,Anaphylaxis ,media_common ,Skin Tests ,biology ,business.industry ,Public health ,medicine.disease ,3. Good health ,030228 respiratory system ,Desensitization, Immunologic ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,biology.protein ,Position paper ,business - Abstract
Drug hypersensitivity reactions (DHR) constitute a major and common public health problem, particularly in children. One of the most severe manifestations of DHR is anaphylaxis, which might be associated with a life-threatening risk. During those past decades, anaphylaxis has received particularly a lot of attention and international consensus guidelines have been recently published. Whilst drug-induced anaphylaxis is more commonly reported in adulthood, less is known about the role of drugs in pediatric anaphylaxis. Betalactam antibiotics and non-steroidal anti-inflammatory drugs are the most commonly involved drugs, probably related to high prescription rates. Diagnosis relies on the recognition of symptoms pattern and is based on complete allergic workup, particularly including skin tests and/or specific IgE. However, the real diagnostic value of those tests to diagnose immediate reactions in children remains not well defined for a significant number of the drugs. Generally, a drug provocation test is discussed to confirm or exclude an immediate-onset drug-induced hypersensitivity. Although avoidance of the incriminated drug (and related drug) is the rule, rapid desensitization is useful in selected subgroups of patients. There is a need for large, multicentric studies, to evaluate the real diagnostic value of the currently available skin tests. Moreover there is also a need to develop new diagnostic tests in the future to improve the management of these children.
- Published
- 2018
20. Drug allergy passport and other documentation for patients with drug hypersensitivity - An ENDA/EAACI Drug Allergy Interest Group Position Paper
- Author
-
Jose Julio Laguna, Gianfranco Calogiuri, Sigurveig T. Sigurdardottir, Alla Nakonechna, A. Romano, Josefina Cernadas, J. N. G. Oude Elberink, Violeta Kvedariene, Marina Atanaskovic-Markovic, L. Sedlackova, Eva Rebelo Gomes, H. Rockmann, B Schnyder, Andreas J. Bircher, Lene Heise Garvey, Cristiano Caruso, Torgeir Storaas, Martine Grosber, Javier Fernández, J. Ring, Patrizia Bonadonna, Holger Mosbech, Paula Kauppi, M. Gotua, B. M. Bilo, Pascal Demoly, Anca Mirela Chiriac, Ravishankar Sargur, GJ Burbach, Joanna Makowska, Sevim Bavbek, Ingrid Terreehorst, Mihaela Zidarn, M. Blanca, J. Gooi, N. G. Papadopolous, Knut Brockow, Werner Aberer, Gülfem Çelik, M.J. Torres, Paediatric Pulmonology, Ear, Nose and Throat, Surgical clinical sciences, Skin function and permeability, and Groningen Research Institute for Asthma and COPD (GRIAC)
- Subjects
Drug ,medicine.medical_specialty ,Pediatrics ,media_common.quotation_subject ,Immunology ,Drug allergy ,Health Smart Cards ,CHILDREN ,Documentation ,DIAGNOSIS ,documentation ,Drug Hypersensitivity ,EVENTS ,drug allergy ,drug hypersensitivity ,education ,prevention ,03 medical and health sciences ,0302 clinical medicine ,Surveys and Questionnaires ,HISTORY ,MANAGEMENT ,Humans ,Immunology and Allergy ,Medicine ,Medical history ,MEDICATION ERRORS ,030212 general & internal medicine ,Medical prescription ,Intensive care medicine ,PRESCRIBER ORDER ENTRY ,GENERAL-CONSIDERATIONS ,media_common ,ANAPHYLAXIS ,PENICILLIN ,business.industry ,Risk factor (computing) ,medicine.disease ,3. Good health ,Europe ,030228 respiratory system ,Position paper ,business ,Anaphylaxis - Abstract
The strongest and best-documented risk factor for drug hypersensitivity (DH) is the history of a previous reaction. Accidental exposures to drugs may lead to severe or even fatal reactions in sensitized patients. Preventable prescription errors are common. They are often due to inadequate medical history or poor risk assessment of recurrence of drug reaction. Proper documentation is essential information for the doctor to make sound therapeutic decision. The European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology have formed a task force and developed a drug allergy passport as well as general guidelines of drug allergy documentation. A drug allergy passport, a drug allergy alert card, a certificate, and a discharge letter after medical evaluation are adequate means to document DH in a patient. They are to be handed to the patient who is advised to carry the documentation at all times especially when away from home. A drug allergy passport should at least contain information on the culprit drug(s) including international nonproprietary name, clinical manifestations including severity, diagnostic measures, potential cross-reactivity, alternative drugs to prescribe, and where more detailed information can be obtained from the issuer. It should be given to patients only after full allergy workup. In the future, electronic prescription systems with alert functions will become more common and should include the same information as in paper-based documentation.
- Published
- 2016
21. Genetic variants associated with drugs-induced immediate hypersensitivity reactions: a PRISMA-compliant systematic review
- Author
-
Ingrid Terreehorst, Jean-Christoph Roger J-P Caubet, Luciana Kase Tanno, Josefina Cernadas, M. Gotua, M. Atanaskovic, Pascal Demoly, M. Blanca, Abderrahim Oussalah, Alla Nakonechna, Andreas J. Bircher, A. Barbaud, Antonino Romano, Jose Julio Laguna, Knut Brockow, Cristobalina Mayorga, Jean-Louis Guéant, Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service de Biochimie et Biologie Moléculaire, Nutrition et Métabolisme [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Biomedical Research Institute of Málaga (IBIMA), Service de Dermatologie et Allergologie [CHRU Nancy], Allergy and Immunology Clinic [Royal Liverpool and Broadgreen University Hospital], Royal Liverpool and Broadgreen University Hospital NHS Trust, Immunoallergy Department [Porto], Centro Hospitalar São João EPE, Center for Allergy and Immunology Research [Tbilisi], Department of Dermatology and Allergy Biederstein, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Division of Paediatrics [Geneva], University Hospital of Geneva, University Hospital Basel [Basel], Department of Allergology and Pulmonology [Belgrade], University Children's Hospital [Belgrade], Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Hospital Sírio-Libanês [São Paulo, Brazil], Academisch Medisch Centrum bij, Universiteit van Amsterdam (UvA), Allergy Unit [Cruz Roja-Madrid], Hospital Central de la Cruz Roja San Jose y Santa Adela, and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
- Subjects
Hypersensitivity, Immediate ,Candidate gene ,[SDV]Life Sciences [q-bio] ,Immunology ,Human leukocyte antigen ,Drug Hypersensitivity ,Atopy ,03 medical and health sciences ,0302 clinical medicine ,Genetic variation ,Genetic predisposition ,medicine ,Humans ,Immunology and Allergy ,Genetic Predisposition to Disease ,030212 general & internal medicine ,Allele frequency ,Aspirin ,ddc:618 ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Nonsteroidal anti-inflammatory drugs ,Genetic Variation ,Environmental exposure ,Immunoglobulin E ,medicine.disease ,Anti-Bacterial Agents ,3. Good health ,Beta-lactam antibiotics ,030228 respiratory system ,Genetic predictors ,IgE-mediated drug allergy ,business ,medicine.drug - Abstract
International audience; Drug hypersensitivity includes allergic (AR) and nonallergic reactions (NARs) influenced by genetic predisposition. We performed a systematic review of genetic predictors of IgE-mediated AR and NAR with MEDLINE and PubMed search engine between January 1966 and December 2014. Among 3110 citations, the search selected 53 studies, 42 of which remained eligible. These eligible studies have evaluated genetic determinants of immediate reactions (IR) to beta-lactams (n = 19), NAR against aspirin (n = 12) and other nonsteroidal anti-inflammatory drugs (NSAIDs) (n = 8), and IR to biologics (n = 3). We reported two genomewide association studies and four case–control studies on candidate genes validated by replication. Genes involved in IR to beta-lactams belonged to HLA type 2 antigen processing, IgE production, atopy, and inflammation, including 4 genes validated by replications, HLA-DRA, ILR4, NOD2, and LGALS3. Genes involved in NAR to aspirin belonged to arachidonic acid pathway, membrane-spanning 4A gene family, histamine production pathway, and pro-inflammatory cytokines, while those involved in NAR to all NSAIDs belonged to arachidonic acid pathway and HLA antigen processing pathway. ALOX5 was a common predictor of studies on NAR to both aspirin and NSAIDs. Although these first conclusions could be drawn, this review highlights also the lack of reliable data and the need for replicating studies in contrasted populations, taking into account worldwide allele frequencies, gene–gene interactions, and contrasted situations of environmental exposure.
- Published
- 2016
22. Endotyping of non-allergic, allergic and mixed rhinitis patients using a broad panel of biomarkers in nasal secretions
- Author
-
Christine Segboer, Ingrid Terreehorst, Wytske Fokkens, Cornelis M. van Drunen, Graduate School, Ear, Nose and Throat, and AII - Inflammatory diseases
- Subjects
Male ,Endotype ,Physiology ,lcsh:Medicine ,Plant Science ,Nasal secretion ,Pathology and Laboratory Medicine ,medicine.disease_cause ,Mathematical and Statistical Techniques ,0302 clinical medicine ,Allergen ,Immune Physiology ,Allergies ,Medicine and Health Sciences ,lcsh:Science ,030223 otorhinolaryngology ,Immune Response ,Rhinitis ,Innate Immune System ,Principal Component Analysis ,Multidisciplinary ,Allergic Diseases ,Hepatocyte Growth Factor ,Plant Anatomy ,Interleukin-12 ,Physical Sciences ,Non allergic ,Cytokines ,Pollen ,Female ,medicine.symptom ,Statistics (Mathematics) ,Research Article ,Allergic Rhinitis ,Adult ,Immunology ,Inflammation ,Research and Analysis Methods ,03 medical and health sciences ,Signs and Symptoms ,Diagnostic Medicine ,Respiratory Hypersensitivity ,medicine ,Humans ,In patient ,Statistical Methods ,Secretion ,business.industry ,lcsh:R ,Biology and Life Sciences ,Rhinology ,Molecular Development ,Allergens ,Mixed rhinitis ,Nasal Mucosa ,Otorhinolaryngology ,030228 respiratory system ,Immune System ,Multivariate Analysis ,Chronic Disease ,Nasal Diseases ,lcsh:Q ,Clinical Immunology ,Clinical Medicine ,Physiological Processes ,Complication ,business ,Mathematics ,Biomarkers ,Developmental Biology - Abstract
Background Endotyping chronic rhinitis has proven hardest for the subgroup of non-allergic rhinitis (NAR) patients. While IgE-related inflammation is typical for allergic rhinitis (AR), no markers have been found that can be seen to positively identify NAR. A further complication is that AR and NAR might co-exist in patients with mixed rhinitis. As previous studies have considered only a limited number of inflammatory mediators, we wanted to explore whether a wider panel of mediators could help us refine the endotyping in chronic rhinitis patients. Objective To endotype chronic rhinitis, and non-allergic rhinitis in particular, with help of molecular or cellular markers. Method In this study we included 23 NAR patients without allergen sensitizations and with persistent rhinitis symptoms, 22 pollen sensitized rhinitis patients with seasonal symptoms, 21 mixed rhinitis patients with pollen-related symptoms and persistent symptoms outside of the pollen season, and 23 healthy controls without any symptoms. Nasal secretions were collected outside of pollen season and differences between the endotypes were assessed for a broad range of inflammatory mediators and growths factors using a multiplex ELISA. Results Although we were able to identify two new nasal secretion makers (IL-12 and HGF) that were low in mixed and AR patients versus NAR and healthy controls, the most intriguing outcome is that despite investigating 29 general inflammatory mediators and growth factors no clear profile of non-allergic or mixed rhinitis could be found. Conclusion Classical inflammatory markers are not able to differentiate between non-allergic or mixed rhinitis patients and healthy controls.
- Published
- 2018
23. An EAACI task force report: Recognising the potential of the primary care physician in the diagnosis and management of drug hypersensitivity
- Author
-
Knut Brockow, M.J. Torres, Inmaculada Doña, Esther Moreno, Ingrid Terreehorst, Jean-Christoph Roger J-P Caubet, and M Doyle
- Subjects
Pulmonary and Respiratory Medicine ,Drug ,medicine.medical_specialty ,Urticaria ,media_common.quotation_subject ,Immunology ,Drug allergy ,MEDLINE ,Review ,Primary care ,Skin test ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Hypersensitivity ,medicine ,Immunology and Allergy ,Drug reaction ,Medical prescription ,Intensive care medicine ,Anaphylaxis ,media_common ,business.industry ,Task force ,Primary care physician ,RC581-607 ,Betalactam ,medicine.disease ,030228 respiratory system ,Drug provocation test ,Immunologic diseases. Allergy ,business ,Exanthem ,Non-steroidal anti-inflammatory drugs - Abstract
Adverse drug reactions include drug hypersensitivity reactions (DHRs), which can be immunologically mediated (allergy) or non-immunologically mediated. The high number of DHRs that are unconfirmed and often self-reported is a frequent problem in daily clinical practice, with considerable impact on future prescription choices and patient health. It is important to distinguish between hypersensitivity and non-hypersensitivity reactions by adopting a structured diagnostic approach to confirm or discard the suspected drug, not only to avoid life-threatening reactions, but also to reduce the frequent over-diagnosis of DHRs. Primary care physicians are often the first point of contact for the sufferer of a reaction, as such they have a key role in deciding whether to discard the diagnosis or send the patient for further investigation. In this review, we highlight the importance of diagnosing DHRs, analysing in detail the role of primary care physicians. We describe the common patterns of DHRs and signs of its progression, as well as the indications and contraindications for referring the patient to an allergist. The diagnostic process is described and the possible tests are discussed, which often depend on the drug involved and the type of DHR suspected. We also describe recommendations regarding the avoidance of medication suspected to have caused the reaction and the use of alternatives.
- Published
- 2018
24. EAACI/ENDA Position Paper: Diagnosis and management of hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents
- Author
-
Ingrid Terreehorst, Jean-Christoph Roger J-P Caubet, Chiang Wen Chin, Eva Rebelo Gomes, Natalia Blanca-López, Claude Ponvert, Luciana Kase Tanno, Marina Atanaskovic-Markovic, Ozge Soyer, Miguel Blanca, Francesca Mori, Mona Kidon, Ear, Nose and Throat, and AII - Inflammatory diseases
- Subjects
Male ,Allergy ,Anti-Inflammatory Agents ,Desensitization ,0302 clinical medicine ,Risk Factors ,Immunology and Allergy ,030212 general & internal medicine ,Child ,media_common ,ddc:618 ,Anti-Inflammatory Agents, Non-Steroidal ,3. Good health ,Child, Preschool ,Practice Guidelines as Topic ,Female ,Immunologic/methods ,medicine.drug ,Drug ,medicine.medical_specialty ,Adolescent ,media_common.quotation_subject ,Immunology ,Drug allergy ,Cross Reactions ,Non-Steroidal/immunology/therapeutic use ,Drug Hypersensitivity ,03 medical and health sciences ,Internal medicine ,medicine ,Animals ,Humans ,Antipyretic ,Anaphylaxis/diagnosis/etiology/therapy ,Preschool ,Allergens/immunology/therapeutic use ,Anaphylaxis ,Expert Testimony ,Skin Tests ,business.industry ,Drug Hypersensitivity/diagnosis/therapy ,Allergens ,medicine.disease ,030228 respiratory system ,Non steroidal anti inflammatory ,Desensitization, Immunologic ,Pediatrics, Perinatology and Child Health ,Interest group ,Position paper ,business ,Pediatric population - Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in the pediatric population as antipyretics/analgesics and anti-inflammatory medications. Hypersensitivity (HS) reactions to NSAID in this age group, while similar to adults, have unique diagnostic and management issues. Although slowly accumulating, published data in this age group are still relatively rare and lacking a unifying consensus. This work is a summary of current knowledge and consensus recommendations utilizing both published data and expert opinion from the European Network of Drug Allergy (ENDA) and the Drug Hypersensitivity interest group in the European Academy of Allergy and Clinical Immunology (EAACI). This position paper summarizes diagnostic and management guidelines for children and adolescents with NSAIDs hypersensitivity.
- Published
- 2018
25. β-Lactam Allergy in the Operating Theater: Reply
- Author
-
Ingrid Terreehorst, Bregtje A. Lemkes, Jeroen Hermanides, Markus W. Hollmann, Jan M. Prins, Anesthesiology, ACS - Diabetes & metabolism, AGEM - Endocrinology, metabolism and nutrition, APH - Quality of Care, Amsterdam Gastroenterology Endocrinology Metabolism, Infectious diseases, Ear, Nose and Throat, ACS - Heart failure & arrhythmias, and ACS - Microcirculation
- Subjects
Anesthesiology and Pain Medicine ,Operating theater ,business.industry ,Immunology ,Medicine ,β lactam allergy ,business - Published
- 2019
26. Quality of life is significantly impaired in nonallergic rhinitis patients
- Author
-
Christine L. Segboer, C. M. van Drunen, W. J. Fokkens, Ingrid Terreehorst, P Hellings, Artur Gevorgyan, AII - Amsterdam institute for Infection and Immunity, AII - Inflammatory diseases, Graduate School, Ear, Nose and Throat, and Other Research
- Subjects
Adult ,Male ,medicine.medical_specialty ,Immunology ,Tertiary care ,Treatment satisfaction ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Nonallergic rhinitis ,Quality of life ,Internal medicine ,Surveys and Questionnaires ,medicine ,Immunology and Allergy ,Outpatient clinic ,Humans ,Patient group ,030223 otorhinolaryngology ,Rhinitis ,Otorhinolaryngology department ,business.industry ,Middle Aged ,medicine.disease ,Rhinitis, Allergic ,030228 respiratory system ,Quality of Life ,Female ,business ,Cohort study - Abstract
In contrast to the well-known significant impairment of quality of life (QoL) in allergic rhinitis (AR), the degree of impairment in QoL in non-allergic rhinitis (NAR) remained unknown for a long time, due to a lack of a validated questionnaire to assess QoL in the NAR patient group. In this study a validation for the mini-RQLQ questionnaire in NAR patients was performed, followed by an assessment of QoL in NAR patients compared to AR and healthy controls. Secondly, use of medication and treatment satisfaction in AR and NAR was assessed. The study was an observational cohort study in 287 AR and 160 NAR patients. Patients with symptoms of rhinitis were recruited from a tertiary care outpatient clinic of the Otorhinolaryngology Department. AR was defined as one or more positive results on skin prick testing and clinically relevant symptoms of rhinitis related to their sensitization. NAR was defined as clinically relevant symptoms of rhinitis but without positive results on skin prick testing. The mini-RQLQ was successfully validated in this study for NAR patients. QoL in NAR patients was equally -and for some aspects even more- impaired compared to AR. More than half of both AR and NAR patients were unsatisfied with treatment. These results demonstrate a significant impairment in both AR and NAR patients in their QoL combined with a low treatment satisfaction, emphasizing the need for adequate treatment, especially in the NAR patient group. This article is protected by copyright. All rights reserved
- Published
- 2017
27. Association between atopic manifestations and eosinophilic esophagitis: A systematic review and meta-analysis
- Author
-
Jesús, González-Cervera, Ángel, Arias, Olga, Redondo-González, María M, Cano-Mollinedo, Ingrid, Terreehorst, and Alfredo J, Lucendo
- Subjects
Hypersensitivity, Immediate ,Phenotype ,Risk Factors ,Odds Ratio ,Prevalence ,Humans ,Eosinophilic Esophagitis - Abstract
Eosinophilic esophagitis (EoE) has repeatedly been associated with atopic manifestations, which are reported more frequently in these patients than in the general population.To systematically assess the evidence and strength of the associations between EoE and atopy.We performed a systematic search of the MEDLINE, EMBASE, and SCOPUS databases for case-control studies comparing the frequency of atopic diatheses among patients with EoE and control subjects representing the general population without EoE. Using random-effects meta-analyses, we calculated summary estimates, including 95% confidence intervals (CIs), for bronchial asthma, atopic rhinitis, and eczema. Publication bias risks were assessed by means of funnel plot analysis and specific statistical tests.Of the 2,954 references identified, data were collected from 21 studies, including a total of 53,542 patients with EoE and 54,759 controls. The criteria for defining a diagnosis of atopy in patients with EoE or controls was not structurally considered in most of the studies. Overall, allergic rhinitis was significantly more common among patients with EoE compared with control subjects (odds ratio [OR], 5.09; 95% CI, 2.91-8.90; IDespite pointing to a significant association between atopy and EoE, most of the studies provided no normalized diagnostic criteria for atopy. Further research should provide clear and standardized definitions of such conditions.www.crd.york.ac.uk/PROSPERO Trial Identifier: CRD42016036161.
- Published
- 2016
28. Controversies in Drug Allergy: Drug Allergy Pathways
- Author
-
Ingrid Terreehorst, Anca Mirela Chiriac, Rebecca S. Gruchalla, Paige G. Wickner, Bernard Yu-Hor Thong, Aleena Banerji, Paul-Michel Mertes, and Kimberly G. Blumenthal
- Subjects
medicine.medical_specialty ,Allergy ,Quality management ,Hospitalized patients ,business.industry ,Drug allergy ,Expert consensus ,Guideline ,medicine.disease ,Acute care ,medicine ,Immunology and Allergy ,Intensive care medicine ,business ,Adverse drug reaction - Abstract
Drug allergy pathways are standardized approaches for patients reporting prior drug allergies with the aim of quality improvement and promotion of antibiotic stewardship. At the International Drug Allergy Symposium during the 2018 American Academy of Allergy, Asthma, and Immunology/World Allergy Organization Joint Congress in Orlando, Florida, drug allergy pathways were discussed from international perspectives with a focus on beta-lactam allergy pathways and pragmatic approaches for acute care hospitals. In this expert consensus document, we review current pathways, and detail important considerations in devising, implementing, and evaluating beta-lactam allergy pathways for hospitalized patients. We describe the key patient and institutional factors that must be considered in risk stratification, the central feature of pathway design. We detail shared obstacles to widespread beta-lactam allergy pathway implementation and identify potential solutions to address these challenges.
- Published
- 2019
29. New Findings in Nonallergic Rhinitis and Local Allergic Rhinitis
- Author
-
Ingrid Terreehorst, Carmen Rondon, Cornelis M. van Drunen, Wytske J. Fokkens, Peter Hellings, and Christine L. Segboer
- Subjects
Allergy ,medicine.medical_specialty ,business.industry ,Rhinitis medicamentosa ,Disease ,medicine.disease ,Dermatology ,Mixed rhinitis ,Nonallergic rhinitis ,Otorhinolaryngology ,Inflammatory cascade ,Immunology and Allergy ,Medicine ,Surgery ,Neurology (clinical) ,business - Abstract
Research in rhinitis has primarily focused on allergic rhinitis and important aspects of the disease such as the IgE-mediated inflammatory cascade, the impact on quality of life, the impact on the lower airways, and control and severity of the disease, especially in those patients in which control is not easily obtained. However, a significant number of patients with persistent rhinitis do not show systemic sensitization to aeroallergens or signs of infection. These patients are defined under the umbrella term “nonallergic rhinitis” or “noninfectious rhinitis.” Nonallergic rhinitis comprises a large number of phenotypes and endotypes, such as rhinitis medicamentosa, drug-induced rhinitis, rhinitis of the elderly, idiopathic rhinitis, and local allergic rhinitis. This review describes the new pathophysiology and clinical insights into these different forms of nonallergic rhinitis with special emphasis on local allergy. New recommendations in diagnosis and treatment are given.
- Published
- 2013
30. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis
- Author
-
Ingrid Terreehorst, Anke H. Maitland-van der Zee, Seyed Hamidreza Mahmoudpour, Anthonius de Boer, Folkert W. Asselbergs, Maarten Leusink, Lisa van der Putten, Otolaryngology / Head & Neck Surgery, and CCA - Innovative therapy
- Subjects
Adult ,Male ,medicine.medical_specialty ,Receptor, Bradykinin B2 ,Angiotensin-Converting Enzyme Inhibitors ,Peptidyl-Dipeptidase A ,Pharmacology ,Internal medicine ,Genetics ,medicine ,Humans ,cardiovascular diseases ,Angioedema ,Adverse effect ,Aged ,Polymorphism, Genetic ,business.industry ,Middle Aged ,Critical appraisal ,Cough ,Pharmacogenetics ,Meta-analysis ,ACE inhibitor ,Molecular Medicine ,Female ,Gene polymorphism ,medicine.symptom ,business ,Bradykinin B2 Receptor ,medicine.drug - Abstract
Aim: Angioedema and cough are the two most important adverse effects of ACE inhibitors (ACEIs). Evidence exists that ACEI-related angioedema/cough is partly genetically determined and several genes have been identified to play a role in the development of ACEI-related adverse effects. Materials & methods: This study was performed in order to evaluate the evidence of these genetic associations and ACEIs’ adverse effects. After removing duplicates and critical appraisal, 19 studies were considered to be eligible to review; 14 articles about cough and five articles about angioedema. A separate meta-analysis was performed for the most studied ACE insertion/deletion polymorphism (rs4646994) and its association with cough. Results & conclusion: One gene region (XPNPEP2) was associated with ACEI-induced angioedema in three studies. In our meta-analysis we did not find a significant association between the ACE insertion/deletion polymorphism and ACEI cough. Original submitted 27 September 2012; Revision submitted 6 December 2012
- Published
- 2013
31. Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA2LEN – ARIA Position Paper
- Author
-
J Rosado-Pinto, Valérie Siroux, Cynthia Hohmann, A. Mazon, Olivier Vandenplas, A. Mohammadi, M. P. Orru, W. J. Fokkens, K-H. Carlsen, G. Khayat, Jean Bousquet, Ronald Dahl, Gailen D. Marshall, Jan Brozek, Stefan Wöhrl, J. Ratomaharo, Nanshan Zhong, Paulo Augusto Moreira Camargos, Mario Sánchez-Borges, A. Yorgancioglu, Mariona Pinart, Mika J. Mäkelä, A. Bedbrook, Jordi Sunyer, Philippe-Jean Bousquet, G. Passalacqua, Raphaëlle Varraso, G. S. Ouedraogo, Ingrid Terreehorst, G.W. Canonica, Bianca Beghe, John Wright, Josep M. Antó, I. Pin, J. Ring, F. Kauffmann, Gerard H. Koppelman, William K. Dolen, B. Koffi N'Goran, K. C. Lødrup Carlsen, Brian J. Lipworth, Alkis Togias, A. Ben Kheder, Ruby Pawankar, Christophe Pison, Dennis M. Williams, Osman M. Yusuf, Eugene R. Bleecker, Holger J. Schünemann, M. Roman Rodriguez, Amiran Gamkrelidze, Elina Toskala, B. Hellquist-Dahl, Sergio Bonini, Bénédicte Jacquemin, Eleni Fthenou, E.H.D. Bel, Michael A. Kaliner, Ruta Dubakiene, C. S. Ang, E. Melen, Isabelle Momas, Elena Gimeno-Santos, Klaus F. Rabe, Ferran Ballester, Barbara Rogala, Antonino Romano, Stefano Guerra, Sam Oddie, E.D. Bateman, H. Douagui, Renato T. Stein, Claus Bachert, Robert M. Naclerio, Fernando D. Martinez, Talant Sooronbaev, Rudolph Valenta, K. C. Bergmann, Inger Kull, M. Morais-Almeida, Marjan Kerkhof, Nikolaos G. Papadopoulos, Josep Roca, L.-P. Boulet, L. T. Le, Daniela Porta, F. Martin, K. S. Bennoor, Alfredo Cesario, Piotr Kuna, William W. Busse, S. Nafti, Mübeccel Akdis, Dirkje S. Postma, Phil Lieberman, Désirée Larenas, Aziz Sheikh, Y. Z. Chen, J Mullol, T. Didi, D. Y. Wang, Marta Benet, Peter Schmid-Grendelmeier, David Price, Tari Haahtela, Dominique Valeyre, F. E. R. Simons, I. Annesi-Maesano, Magnus Wickman, A. Andrianarisoa, Giovanni Viegi, Pascal Demoly, A. El-Meziane, C. E. Baena-Cagnani, Ulf Darsow, S. Palkonen, F. Berrissoul, X. Basagana, R. Gerth van Wijk, J. O. B. Hourihane, B. Pigearias, A. L. Boner, T. D. Nyembue, B. Samolinski, Y. Okamoto, W. Carr, C. van Weel, Marek L. Kowalski, Christopher E. Brightling, Thomas Keil, D. Rezagui, D. J. Costa, Todor A. Popov, Eli O. Meltzer, Ioana Agache, Marcus Maurer, Thomas B. Casale, T. Bieber, Charles Auffray, Antonella Muraro, K. Ohta, T. Zuberbier, Yousser Mohammad, Henriette A. Smit, Manolis Kogevinas, Dermot Ryan, Iris Lavi, Marc Humbert, Sakari Reitamo, J. Just, Martijn C. Nawijn, M. Beji, Bassam Mahboub, F. Mihaltan, Peter H. Howarth, Alvaro A. Cruz, Cevdet Ozdemir, L. Namazova-Baranova, Y. Tremblay, M. E. Zernotti, Adnan Custovic, C. Bindslev Jensen, João Fonseca, Robyn E O'Hehir, O. Kalayci, H. Haddad, Andrew Bush, L. Cox, Mihaela Zidarn, Anca-Mirela Chiriac, H. J. Zar, Judith Garcia-Aymerich, G. K. Scadding, Peter J. Sterk, Richard G. Roberts, Maria Vassilaki, P. Panzner, and P W Hellings
- Subjects
medicine.medical_specialty ,business.industry ,Public health ,Immunology ,macromolecular substances ,General Medicine ,Atopic dermatitis ,medicine.disease ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,Disease severity ,Epidemiology ,medicine ,Physical therapy ,Immunology and Allergy ,Position paper ,Disease process ,030212 general & internal medicine ,Intensive care medicine ,business ,Chronic urticaria ,Asthma - Abstract
Concepts of disease severity, activity, control and responsiveness to treatment are linked but different. Severity refers to the loss of function of the organs induced by the disease process or to the occurrence of severe acute exacerbations. Severity may vary over time and needs regular follow-up. Control is the degree to which therapy goals are currently met. These concepts have evolved over time for asthma in guidelines, task forces or consensus meetings. The aim of this paper is to generalize the approach of the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases (rhinitis, chronic rhinosinusitis, chronic urticaria and atopic dermatitis) in order to have a uniform definition of severity, control and risk, usable in most situations. It is based on the appropriate diagnosis, availability and accessibility of treatments, treatment responsiveness and associated factors such as comorbidities and risk factors. This uniform definition will allow a better definition of the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology), public health purposes, education and the discovery of novel therapies.
- Published
- 2012
32. Continuation of angiotensin converting enzyme inhibitor therapy, in spite of occurrence of angioedema
- Author
-
Folkert W. Asselbergs, Ingrid Terreehorst, Anke H. Maitland-van der Zee, Patrick C. Souverein, Seyed Hamidreza Mahmoudpour, Anthonius de Boer, Other Research, Paediatric Pulmonology, Ear, Nose and Throat, and Pulmonology
- Subjects
Time Factors ,drug safety ,Letter ,recurrent disease ,Angiotensin-Converting Enzyme Inhibitors ,Pharmacology ,angioneurotic edema ,Risk Factors ,dipeptidyl carboxypeptidase inhibitor ,Taverne ,Non-U.S. Gov't ,Netherlands ,Incidence ,adult ,Incidence (epidemiology) ,Research Support, Non-U.S. Gov't ,drug effect ,Follow up studies ,risk assessment ,Angiotensin converting enzyme inhibitor therapy ,cohort analysis ,Survival Rate ,Prescribing pattern ,female ,priority journal ,drug withdrawal ,Hypertension ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Prescription Drugs ,drug exposure ,Drug-Related Side Effects and Adverse Reactions ,Adverse drug reaction ,Research Support ,male ,Internal medicine ,medicine ,Humans ,follow up ,human ,Angioedema ,Drug-induced angioedema ,Survival rate ,prescription ,treatment duration ,business.industry ,disease association ,medicine.disease ,major clinical study ,Endocrinology ,Angiotensin converting enzyme inhibitor ,business ,Follow-Up Studies - Published
- 2015
33. The in vitro diagnosis of drug allergy: status and perspectives
- Author
-
Ingrid Terreehorst, Edward F. Knol, Didier G. Ebo, Cristobalina Mayorga, J. Leysen, and Aurore Rozières
- Subjects
biology ,business.industry ,ELISPOT ,Immunology ,Drug allergy ,medicine.disease ,Immunoglobulin E ,In vitro ,Clinical Practice ,Ige mediated ,Lymphocyte transformation ,biology.protein ,Immunology and Allergy ,Medicine ,Drug reaction ,business - Abstract
Adverse drug reactions (ADR) can result from immune-mediated (drug allergy) and nonimmune-mediated mechanisms. In both types of reaction, conclusive diagnosis and appropriate management remain major problems in daily clinical practice. This review summarizes the potentials and shortcomings of the currently available in vitro tests in the diagnosis of immediate (mostly IgE mediated) and nonimmediate (mostly T-cell mediated) drug allergy, particularly quantification of specific IgE, flow-assisted analysis of in vitro activated lymphocytes and basophils and the enzyme-linked immunosorbent spot.
- Published
- 2011
34. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA2LEN taskforce position paper
- Author
-
Emek Kocatürk, Dimitris Kalogeromitros, Alessandro Fiocchi, Clive Grattan, Fulvio Braido, Ana Giménez-Arnau, Philippe-Jean Bousquet, Enrico Compalati, A. Todo Bom, Anabela Mota-Pinto, Sarbjit S. Saini, Elias Toubi, Carolina Lombardi, R. Gerth van Wijk, Carsten Bindslev-Jensen, Jean Bousquet, Gianenrico Senna, Jean-Jacques Grob, Giorgio Walter Canonica, Erminia Ridolo, Ingrid Terreehorst, T. Zuberbier, S. La Grutta, Zenon Brzoza, Marcus Maurer, Kiran Godse, Mario Sánchez-Borges, Ilaria Baiardini, and W. J. Fokkens
- Subjects
medicine.medical_specialty ,Angioedema ,business.industry ,Immunology ,MEDLINE ,medicine.disease ,Surgery ,Clinical trial ,Quality of life (healthcare) ,immune system diseases ,Family medicine ,parasitic diseases ,medicine ,Immunology and Allergy ,Position paper ,Patient-reported outcome ,medicine.symptom ,skin and connective tissue diseases ,business ,Disease burden ,Asthma - Abstract
To cite this article: Baiardini I, Braido F, Bindslev-Jensen C, Bousquet PJ, Brzoza Z, Canonica GW, Compalati E, Fiocchi A, Fokkens W, Gerth van Wijk R, Gimenez-Arnau A, Godse K, Grattan C, Grob JJ, La Grutta S, Kalogeromitros D, Kocaturk E, Lombardi C, Mota-Pinto A, Ridolo E, Saini SS, Sanchez-Borges M, Senna GE, Terreehorst I, Todo Bom A, Toubi E, Bousquet J, Zuberbier T, Maurer M. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA2LEN taskforce position paper. Allergy 2011; 66: 840–844. Abstract The aim of this Global Allergy and Asthma European Network (GA2LEN) consensus report is to provide recommendations and suggestions for assessing patient-reported outcomes (PROs) including health-related quality of life in patients with urticaria. We recommend that PROs should be used both in clinical trials and routine practice for the evaluation of urticaria patients. We suggest that PROs should be considered as the primary outcome of future clinical trials. Two validated and disease-specific instruments for assessing PROs are available, the urticaria activity score (for symptoms) and the chronic urticaria questionnaire on quality of life CU-Q2oL. This latter tool, CU-Q2oL, is available in many languages and should be preferred, where available, over more generic instruments for assessing urticaria-specific effects on quality of life. CU-Q2oL is only suited for the investigation of patients with chronic spontaneous urticaria. Similar instruments for other forms of urticaria have yet to be developed and validated. Also, tools for assessing other chronic spontaneous urticaria PROs besides quality of life and symptoms are needed.
- Published
- 2011
35. Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA2LEN taskforce position paper
- Author
-
F. Braido, Enrico Compalati, Carolina Lombardi, S. La Grutta, Jean Bousquet, R. Gerth van Wijk, Philippe-Jean Bousquet, Erminia Ridolo, Anabela Mota Pinto, Ingrid Terreehorst, Alessandro Fiocchi, Zenon Brzoza, Ilaria Baiardini, T. Zuberbier, Gianenrico Senna, Giorgio Walter Canonica, Marcus Maurer, A. Todo Bom, and W. J. Fokkens
- Subjects
Health related quality of life ,medicine.medical_specialty ,business.industry ,Immunology ,medicine.disease ,humanities ,Unmet needs ,Surgery ,Clinical trial ,Quality of life (healthcare) ,Lung disease ,Family medicine ,medicine ,Immunology and Allergy ,Position paper ,business ,Asthma - Abstract
The GA 2 LEN taskforce on Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) published in 2009 a position paper concerning PROS and HRQoL assessment in clinical trials on allergy. Because of the specificity of this topic in asthma and rhinitis, specific recommendations are needed. The aim of this position paper is to define PROs and their meaning in asthma and rhinitis research, explore the available tools to provide criteria for a proper choice, identify patientrelated factor which could influence PROs assessment, define specific recommendations for assessment, analysis and results spreading, underline the unexplored areas and unmet needs. PROs assessment is gaining increasing importance, and it must be performed with a rigorous methodological procedure and using validated tools. This approach enables to better understand patient-related factors influencing clinical trials and real-life management outcomes, identify patients subgroups that can benefit from specific treatment and management plan and tailor treatment to address PROs (not only physician-defined targets) to improve asthma and rhinitis management.
- Published
- 2010
36. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GA2LEN platform. The Galenda project
- Author
-
E. Van Ganse, Marina Atanaskovic-Markovic, Nikolaos G. Papadopoulos, P.M. Mertes, Philippe-Jean Bousquet, Andreas J. Bircher, A. Sidoroff, A. Bijl, Maria L. Sanz, Hans F. Merk, A. Barbaud, Eva Rebelo Gomes, Claude Ponvert, Marek L. Kowalski, M. Blanca, Silvia Caimmi, Knut Brockow, Antonino Romano, Jean-Pierre Daurès, G.W. Canonica, Andrzej Szczeklik, M.J. Torres, B. Sachs, Javier Fernández, Ewa Nizankowska-Mogilnicka, T. Zuberbier, Werner J. Pichler, Pascal Demoly, A.L. de Weck, Violeta Kvedariene, P. Martins, Barbro Dahlén, Patrizia Bonadonna, Josefina Cernadas, Munir Pirmohamed, Werner Aberer, Ingrid Terreehorst, M. Salapatas, B. Arnoux, Peter Burney, Jean-Louis Guéant, and J. Ring
- Subjects
Allergy ,Clinical immunology ,Database ,business.industry ,Operating procedures ,Immunology ,Drug allergy ,MEDLINE ,medicine.disease ,computer.software_genre ,Spontaneous reporting ,Pharmacovigilance ,medicine ,Immunology and Allergy ,Drug reaction ,business ,computer - Abstract
Nonallergic hypersensitivity and allergic reactions are part of the many different types of adverse drug reactions (ADRs). Databases exist for the collection of ADRs. Spontaneous reporting makes up the core data-generating system of pharmacovigilance, but there is a large under-estimation of allergy/hypersensitivity drug reactions. A specific database is therefore required for drug allergy and hypersensitivity using standard operating procedures (SOPs), as the diagnosis of drug allergy/hypersensitivity is difficult and current pharmacovigilance algorithms are insufficient. Although difficult, the diagnosis of drug allergy/hypersensitivity has been standardized by the European Network for Drug Allergy (ENDA) under the aegis of the European Academy of Allergology and Clinical Immunology and SOPs have been published. Based on ENDA and Global Allergy and Asthma European Network (GA(2)LEN, EU Framework Programme 6) SOPs, a Drug Allergy and Hypersensitivity Database (DAHD((R))) has been established under FileMaker((R)) Pro 9. It is already available online in many different languages and can be accessed using a personal login. GA(2)LEN is a European network of 27 partners (16 countries) and 59 collaborating centres (26 countries), which can coordinate and implement the DAHD across Europe. The GA(2)LEN-ENDA-DAHD platform interacting with a pharmacovigilance network appears to be of great interest for the reporting of allergy/hypersensitivity ADRs in conjunction with other pharmacovigilance instruments.
- Published
- 2009
37. POSTER DISCUSSION SESSIONS
- Author
-
Ingrid Terreehorst, A.C. Linden, A.J.H. van Vliet, L.A. Weger, Pieter S. Hiemstra, and W.J. Slikke
- Subjects
Ragweed ,Agronomy ,Immunology ,Immunology and Allergy ,Biology ,biology.organism_classification - Published
- 2008
38. Wytyczne dotyczące rozpoznawania i postępowania w eozynofilowym zapaleniu przełyku u dzieci i dorosłych: oparte na faktach stwierdzenia i rekomendacje
- Author
-
Helen Larsson, Ángel Arias, Martin Storr, Javier Molina-Infante, Jorge Amil Dias, Albert J. Bredenoord, Ulrike von Arnim, Christian Bussmann, Ingrid Terreehorst, Jesús González-Cervera, Jukka Ronkainen, Alfredo J. Lucendo, Joaquín Rodríguez-Sánchez, Alberto Ravelli, Alexandra Papadopoulou, Cecilio Santander, Stephan Miehlke, Mogens Bove, Alain M. Schoepfer, A. Straumann, and Stephen Attwood
- Abstract
Eozynofilowe zapalenie przełyku (eosinophilic esophagitis − EoE) jest najczęstszą chorobą przełyku, prowadzącą do dysfagii i zaburzeń odżywiania u dzieci i młodych dorosłych. W związku z tym oraz z uwagi na znaczną liczbę opublikowanych w ostatnim czasie badań na temat EoE bardzo istotna jest optymalizacja rozpoznania i leczenia. Towarzystwa UEG, EAACI, ESPGHAN i EUREOS uznały za konieczne zaktualizowanie wytycznych w zakresie etiologii, epidemiologii, diagnostyki i terapii EoE. Metody. Zastosowano metodologię zgodną z AGREE II (Appraisal of Guidelines for Research and Evaluation) i GRADE (Grading of Recommendations Assessment, Development, and Evaluation), czyli aktualnymi standardami oceny dowodów w formułowaniu rekomendacji.Wyniki. Wytyczne zawierają uaktualnione dane na temat etiologii EoE, epidemiologii, czynników ryzyka, chorób towarzyszących i historii naturalnej EoE u dzieci i dorosłych. Dostarczają informacji o badaniach diagnostycznych i kryteriach rozpoznania, procedurach monitorowania oraz prezentują oparte na faktach zalecenia i rekomendacje dotyczące różnych metod leczenia.Wnioski. W wytycznych zaproponowano oparte na faktach rekomendacje dotyczące rozpoznawania, leczenia i nadzoru pacjentów z EoE.
- Published
- 2017
39. Association between atopic manifestations and eosinophilic esophagitis
- Author
-
Jesús González-Cervera, María M. Cano-Mollinedo, Ángel Arias, Alfredo J. Lucendo, Ingrid Terreehorst, and Olga Redondo-González
- Subjects
Pulmonary and Respiratory Medicine ,Allergy ,medicine.medical_specialty ,education.field_of_study ,business.industry ,Atopic Rhinitis ,Immunology ,Population ,Publication bias ,medicine.disease ,Dermatology ,Atopy ,03 medical and health sciences ,0302 clinical medicine ,Meta-analysis ,Immunology and Allergy ,Medicine ,030211 gastroenterology & hepatology ,030212 general & internal medicine ,business ,Eosinophilic esophagitis ,education ,Asthma - Abstract
Background Eosinophilic esophagitis (EoE) has repeatedly been associated with atopic manifestations, which are reported more frequently in these patients than in the general population. Objective To systematically assess the evidence and strength of the associations between EoE and atopy. Methods We performed a systematic search of the MEDLINE, EMBASE, and SCOPUS databases for case-control studies comparing the frequency of atopic diatheses among patients with EoE and control subjects representing the general population without EoE. Using random-effects meta-analyses, we calculated summary estimates, including 95% confidence intervals (CIs), for bronchial asthma, atopic rhinitis, and eczema. Publication bias risks were assessed by means of funnel plot analysis and specific statistical tests. Results Of the 2,954 references identified, data were collected from 21 studies, including a total of 53,542 patients with EoE and 54,759 controls. The criteria for defining a diagnosis of atopy in patients with EoE or controls was not structurally considered in most of the studies. Overall, allergic rhinitis was significantly more common among patients with EoE compared with control subjects (odds ratio [OR], 5.09; 95% CI, 2.91–8.90; I 2 = 86.7%) as were bronchial asthma (OR, 3.01; 95% CI, 1.96–4.62; I 2 = 84.5%) and eczema (OR, 2.85; 95% CI, 1.87–4.34; I 2 = 57.1%). Food allergies and other atopic conditions were also assessed. No significant publication bias was found for studies dealing with allergic rhinitis and eczema in EoE. Conclusion Despite pointing to a significant association between atopy and EoE, most of the studies provided no normalized diagnostic criteria for atopy. Further research should provide clear and standardized definitions of such conditions. Trial Registration www.crd.york.ac.uk/PROSPERO Trial Identifier: CRD42016036161.
- Published
- 2017
40. Hypersensitivity Reactions to Non-Betalactam Antibiotics in Children: An Extensive Review
- Author
-
Francesca Mori, Eva Rebelo Gomes, Knut Brockow, Marina Atanaskovic-Markovic, Ingrid Terreehorst, Jean-Christoph Roger J-P Caubet, and Semanur Kuyucu
- Subjects
medicine.medical_specialty ,Pediatrics ,medicine.drug_class ,Immunology ,Provocation test ,Drug allergy ,Antibiotics ,Quinolones ,beta-Lactams ,Drug Hypersensitivity ,medicine ,Animals ,Humans ,Immunology and Allergy ,Drug reaction ,Child ,Betalactam antibiotics ,Sulfonamides ,ddc:618 ,business.industry ,Allergens ,medicine.disease ,Dermatology ,3. Good health ,Management strategy ,Pediatrics, Perinatology and Child Health ,Immunization ,Macrolides ,business - Abstract
In contrast to hypersensitivity reactions (HSRs) to -lactam antibiotics in children, studies about HSR to non--lactam antibiotics (NBLAs) such as sulfonamides, macrolides, quinolones, and antituberculosis agents are scarce, and information is generally limited to case reports. The aim of this extensive review was to summarize our present knowledge on clinical characteristics, evaluation, and management of HSR to NBLAs in children based on the literature published between 1980 and 2013. NBLAs have been reported to induce a wide spectrum of HSRs from mild eruptions to severe, and sometimes fatal, systemic drug reactions, especially in some high-risk groups. The diagnosis relied upon history and remained unconfirmed by allergological tests in most of the cases. Obtaining a detailed history is valuable in the diagnosis of suspected reactions to NBLAs. Diagnostic in vivo and in vitro tests for NBLAs lack validation, which makes the diagnosis challenging. The definitive diagnosis of NBLA hypersensitivity frequently depends upon drug provocation tests. Studies including children showed that only 7.8 to 36% of suspected immediate and delayed HSRs to NBLAs could be confirmed by skin and/or provocation tests. Therefore, a standardized diagnostic approach and management strategy should be developed and employed for pediatric patients in the evaluation of suspected HSRs to NBLAs, some of which may be critical and unreplaceable in certain clinical situations. image
- Published
- 2014
41. Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper
- Author
-
Pm Mertes, S Nasser, Am Chiriac, María José Torres, Miguel Blanca, Pascal Demoly, E Castro, S. Testi, Knut Brockow, M. B. Bilò, J. Ring, Lh Garvey, Axel Trautmann, B Schnyder, Paolo Campi, Audrey Romano, A. Barbaud, Andreas J. Bircher, Holger Mosbech, Ingrid Terreehorst, Carla Lombardo, B Bonadonna, J Gooi, Martine Grosber, Kathrin Scherer, M. Pagani, Werner Aberer, Marina Atanaskovic-Markovic, Jr Cernadas, Surgical clinical sciences, Specialities, Skin function and permeability, Other Research, Paediatric Pulmonology, and Ear, Nose and Throat
- Subjects
Hypersensitivity, Immediate ,Drug ,medicine.medical_specialty ,Allergy ,diagnosis ,media_common.quotation_subject ,Immunology ,Drug allergy ,MEDLINE ,skin test ,Pharmacology ,Sensitivity and Specificity ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,intradermal test ,medicine ,Humans ,Immunology and Allergy ,Hypersensitivity, Delayed ,Intensive care medicine ,Skin Tests ,media_common ,business.industry ,Perioperative ,Skin test ,medicine.disease ,3. Good health ,Interest group ,Position paper ,business ,drug allergy ,drug hypersensitivity ,030215 immunology - Abstract
Skin tests are of paramount importance for the evaluation of drug hypersensitivity reactions. Drug skin tests are often not carried out because of lack of concise information on specific test concentrations. The diagnosis of drug allergy is often based on history alone, which is an unreliable indicator of true hypersensitivity.To promote and standardize reproducible skin testing with safe and nonirritant drug concentrations in the clinical practice, the European Network and European Academy of Allergy and Clinical Immunology (EAACI) Interest Group on Drug Allergy has performed a literature search on skin test drug concentration in MEDLINE and EMBASE, reviewed and evaluated the literature in five languages using the GRADE system for quality of evidence and strength of recommendation. Where the literature is poor, we have taken into consideration the collective experience of the group.We recommend drug concentration for skin testing aiming to achieve a specificity of at least 95%. It has been possible to recommend specific drug concentration for betalactam antibiotics, perioperative drugs, heparins, platinum salts and radiocontrast media. For many other drugs, there is insufficient evidence to recommend appropriate drug concentration. There is urgent need for multicentre studies designed to establish and validate drug skin test concentration using standard protocols. For most drugs, sensitivity of skin testing is higher in immediate hypersensitivity compared to nonimmediate hypersensitivity.
- Published
- 2014
42. Phenotype Standardization of Angioedema in the Head and Neck Region Caused by Agents Acting on the Angiotensin System
- Author
-
Mia Wadelius, Ingrid Terreehorst, Ekaterina V Baranova, Pär Hallberg, Gunilla Islander, Munir Pirmohamed, Leif Nordang, Colin N. A. Palmer, Ana Alfirevic, Svante Hugosson, Karin Sköldefors, Malgorzata Karawajczyk, Qun-Ying Yue, Sara E. Marshall, and Anke-Hilse Maitland-van der Zee
- Subjects
Bradykinin ,Angiotensin-Converting Enzyme Inhibitors ,Review ,Pharmacology and Toxicology ,030204 cardiovascular system & hematology ,Pharmacology ,03 medical and health sciences ,chemistry.chemical_compound ,Angiotensin Receptor Antagonists ,0302 clinical medicine ,Risk Factors ,immune system diseases ,Renin–angiotensin system ,Medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Angioedema ,Adverse effect ,Head and neck ,skin and connective tissue diseases ,biology ,business.industry ,food and beverages ,Angiotensin-converting enzyme ,Farmakologi och toxikologi ,Phenotype ,3. Good health ,chemistry ,biology.protein ,medicine.symptom ,business ,Head ,Neck - Abstract
Angioedema is a potentially life-threatening adverse reaction to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. To study the genetic etiology of this rare adverse event, international consortia and multicenter recruitment of patients are needed. To reduce patient heterogeneity, we have standardized the phenotype. In brief, it comprises swelling in the head and neck region that first occurs during treatment. It should not coincide with urticaria or have another likely cause such as hereditary angioedema.
- Published
- 2014
43. Managing a child with possible allergy to vaccine
- Author
-
Knut Brockow, Eva Rebelo Gomes, Philippe Eigenmann, Odilija Rudzeviciene, Jean-Christoph Roger J-P Caubet, Ingrid Terreehorst, Other Research, Paediatric Pulmonology, and Ear, Nose and Throat
- Subjects
Allergy ,Pediatrics ,medicine.medical_specialty ,ddc:618 ,business.industry ,Immunology ,Histamine Antagonists ,Allergens ,Immunoglobulin E ,Diphtheria-Tetanus-acellular Pertussis Vaccines ,medicine.disease ,Injections, Intramuscular ,Pediatrics, Perinatology and Child Health ,Hypersensitivity ,Humans ,Immunology and Allergy ,Medicine ,Female ,Diagnostic Errors ,Child ,business ,Aluminum ,Skin Tests - Abstract
Similarly to other medications, vaccines may be responsible for allergic reactions. Although IgE-mediated allergies to vaccine are extremely rare, they are clearly overdiagnosed. Indeed, accurate diagnosis of vaccine allergy is important not only to prevent serious or even life-threatening reactions, but also to avoid unnecessary vaccine restriction. Systematic approaches have been proposed and, if implemented, will likely reduce the number of children being inappropriately labeled as allergic to vaccine. In diagnosis of vaccine allergy, the patient's history is central although not sufficient. In case of suspicion of an allergy, the child should be referred to an allergist in order to perform a complete allergy workup, based primarily on skin tests and/or specific IgE. Highlighting the most recent literature, this article will address the management of children with a possible allergy to vaccine.
- Published
- 2014
44. Intranasal capsaicin is lacking therapeutic effect in perennial allergic rhinitis to house dust mite. A placebo-controlled study
- Author
-
Ingrid M. Garrelds, Ingrid Terreehorst, S. Popering, R. Gerth van Wijk, Paul G.H. Mulder, and H. M. Blom
- Subjects
House dust mite ,Allergy ,biology ,business.industry ,Immunology ,Therapeutic effect ,medicine.disease_cause ,Placebo ,medicine.disease ,biology.organism_classification ,Atopy ,Allergen ,medicine ,Immunology and Allergy ,Nasal administration ,Nasal Lavage Fluid ,business - Abstract
In a recent placebo-controlled study we demonstrated that capsaicin is an efficacious substance in the treatment of non-allergic non-infectious rhinitis. In this study the therapeutic effect lasted more than 9 months. This effect was not based on modulation of inflammation. To evaluate the effect of repeated application of capsaicin to patients with a nasal allergy to house dust mites (HDM), using the same treatment protocol as recently introduced in the treatment of non-allergic patients. Twenty-six patients with rhinitis, 15 females and 11 males (range: 20–46 years; mean 30.5), allergic to HDM were treated with either capsaicin or placebo in a double-blind, placebo-controlled, parallel group design. Nasal reactivity to HDM expressed as nasal symptoms, albumin and leukotriene levels in nasal lavage fluid and responsiveness to histamine, assessed as symptoms before and 6 weeks after treatment, were used to compare both treatment groups. In addition, visual analogue scales and rhinitis quality of life (RQL) assessment before, 6 weeks after and 3 months after treatment were used as outcome variables. No significant effect of capsaicin on nasal challenge tests with HDM (nasal symptoms, albumin and leukotriene levels), on VAS or RQL outcome 6 weeks or 3 month's after treatment, was demonstrated. Capsaicin did have a small effect on the area of the curve (AUC) of histamine dose response curves (P = 0.03). Desensitization with capsaicin in doses sufficient to control symptoms in patients with severe non-allergic rhinitis is lacking therapeutic effect in perennial allergic rhinitis.
- Published
- 2000
45. Birch pollen sensitization with cross-reactivity to food allergens predominates in adults with eosinophilic esophagitis
- Author
-
B. D. van Rhijn, Berber Vlieg-Boerstra, Albert J. Bredenoord, Andreas J. Smout, Serge A. Versteeg, R. van Ree, Aline B. Sprikkelman, Ingrid Terreehorst, Other departments, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Experimental Immunology, Paediatric Pulmonology, Other Research, Ear, Nose and Throat, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, and Gastroenterology and Hepatology
- Subjects
Adult ,Male ,Immunology ,Cross Reactions ,medicine.disease_cause ,Cross-reactivity ,Young Adult ,Allergen ,Food allergy ,Pollen ,medicine ,Respiratory Hypersensitivity ,otorhinolaryngologic diseases ,Immunology and Allergy ,Animals ,Humans ,Eosinophilic esophagitis ,Sensitization ,Betula ,House dust mite ,biology ,business.industry ,Pyroglyphidae ,Eosinophilic Esophagitis ,Allergens ,Middle Aged ,medicine.disease ,biology.organism_classification ,medicine.anatomical_structure ,Cynodon ,Female ,business ,Food Hypersensitivity - Abstract
EoE patients show variable sensitization patterns to food and aeroallergens. The value of allergy testing in adult EoE patients is unclear. Component-resolved diagnosis (CRD) may offer additional insights into sensitization patterns. The aim of this study was to characterize sensitization patterns in adult EoE patients using CRD. Serum from 76 patients (17 female), age 38.6 ± 1.5 years, was analyzed for reactivity to 112 different allergen components using an immuno-solid-phase allergen chip (ISAC). We observed any sensitization in 59 patients (78%), of which 54 patients were polysensitized. Aeroallergen sensitization, mostly against components of grass or tree pollen, or house dust mite, was observed in 74% of the patients. Birch pollen (rBet v 1) sensitization with cross-reactivity to food allergen components was observed in 30 patients (39%). In conclusion, food sensitizations in EoE patients are mainly caused by cross-reactivity to food allergens after primary birch pollen sensitization. Pollen and food sensitizations may cause or maintain esophageal inflammation in EoE patients. CRD provides more insight into sensitization patterns, identifies additional food allergen sensitizations and might be useful to direct dietary therapy in EoE.
- Published
- 2013
46. Research needs in allergy: an EAACI position paper, in collaboration with EFA
- Author
-
François Spertini, James Gardner, Felicia Manole, Annalisa Santucci, Bodo Niggemann, Ronald Vanree, Victoria Cardona, Breda Flood, Roger Lauener, Michael R. Perkin, Franziska Ruëff, Hans Jürgen Hoffmann, Adriano Mari, B Schnyder, Aline B. Sprikkelman, Jürgen Schwarze, Marcin Kurowski, Margitta Worm, Lilit Hovhannisyan, Clive Grattan, B. M. Bilo, Javier Fernández, Matteo Bonini, Darío Antolín-Amérigo, Marta Ferrer, Stefano Del Giacco, Fulvio Braido, Svetlana Sergejeva, Jon Genuneit, Karin Hoffmann-Sommergruber, Paraskevi Mangina, Carsten Flohr, Gianni Passalacqua, Nicolette W. deJong, Filippo Fassio, Antonella Muraro, Jan Demonchy, Carsten B. Schmidt-Weber, Paraskevi Xepapadaki, Radoslaw Spiewak, Alexandra F. Santos, Moises A. Calderon, Chrysanthi Skevaki, Roberta Savli, Montserrat Fernandez Rivas, Liam O'Mahony, Susanna Palkonen, Eckard Hamelmann, Paula Robson-Ansley, Claudia Traidl-Hoffmann, Lars K. Poulsen, Miguel Blanca, Enrico Heffler, Jean-Luc Fauquert, Thomas Werfel, Maia Rukhadze, Constantinos Pitsios, Peter Burney, Frode L. Jahnsen, Elina Toskala, Ines Swoboda, Cemal Cingi, Pascal Demoly, Marek Jutel, Ingrid Terreehorst, Nikolaos Douladiris, Alberto Papi, Susanne Lau, Jean-Christoph Roger J-P Caubet, George N. Konstantinou, Peter Schmid-Grendelmeier, Gianenrico Senna, Valérie Hox, Sevcan Celenk, Kirsty Logan, Gunnar Nilsson, Clare Mills, Claudio Rhyner, Andrea Siracusa, Jeroen Buters, Paul Whitacker, Sevim Bavbek, Antti Lauerma, Edward F. Knol, Heidi Makrinioti, Mariana Couto, Cezmi A. Akdis, Antoine Magnan, Cansin Sackesen, Isabella Annesi-Maesano, Berber Vlieg-Boerstra, Ulrike Raap, Knut Brockow, Philippe Gevaert, Gunter J. Sturm, Carina Venter, Santiago Quirce, Sven Seys, Philippe Eigenmann, Nikolaos G. Papadopoulos, Rodrigo Rodrigues Alves, Jacques Gayraud, Christian Scharf, Monika Raulf-Heimsoth, Serena O'Neil, Ioana Agache, Markus Ollert, Jörg Kleine-Tebbe, Francesco Annunziato, Odilija Rudzeviciene, Gianni Pala, Oliver Pfaar, Christian Apfelbacher, Massimo Triggiani, Ervinç Mingomataj, Patrizia Bonadonna, Joanna Makowska, Carmen Rondon, Gabriele Rumi, Lars-Olaf Cardell, Anna Groblewska, Pia Allegri, Milena Sokolowska, Zeljka Roje, Ömer Kalayci, Peter Hellings, Graham Roberts, Jan Lötvall, Angel Mazon, Adnan Custovic, Indre Butiene, Ewa Cichocka-Jarosz, Isabel Skypala, Ayse Fusun Kalpaklioglu, Onur Boyman, Ewa Bogacka, Medical Research Council (MRC), Allergy Department, 2nd Pediatric Clinic, Transylvania University, Ankara University, University Hospital Ospedali Riuniti, Allergy & Respiratory Diseases Clinic - DIMI, Università degli studi di Genova = University of Genoa (UniGe), Vall d'Hebron University Hospital [Barcelona], Respiratory Research Group, University of Manchester [Manchester]-School of Translational Medicine, Department of Allergology, University Hospital Groningen, Département Pneumologie et Addictologie, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pediatric Allergy Unit, Geneva University Hospital (HUG)-Children's Hospital, Allergologie, Polyclinique de l'Ormeau, Dermatology Centre, Norfolk & Norwich University Hospital, Dipartimento di Scienze Mediche, Università degli studi di Torino = University of Turin (UNITO), Department of Otorhinolaryngology, Head, and Neck Surgery, University Hospital Leuven, Department of Clinical Immunology, Wrocław Medical University, Department of Dermatology/Allergology (G02* 124), University Medical Center [Utrecht], Department of Internal Medicine, University of Gothenburg (GU)-Krefting Research Centre, Department of Pediatrics, Università degli Studi di Padova = University of Padua (Unipd), Laboratory of Medical Allergology, Copenhagen University Hospital at Gentofte-Allergy Clinic, Faculty of Medicine, University of Southampton, Allergy Unit - Department of Dermatology, Universität Zürich [Zürich] = University of Zurich (UZH), Neurologica Clinic, Università degli Studi di Salerno = University of Salerno (UNISA)-University of Naples Federico II = Università degli studi di Napoli Federico II, Department of Experimental Immunology, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA), Department of Dermatology and Allergy, Hannover Medical School [Hannover] (MHH), European Federation of Allergy (EFA), Airways Diseases Patients' Associations, Ophthamology epmn, Uveitis Center-Rapallo Hospital, Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Università degli Studi di Firenze = University of Florence (UniFI)-DENOTHE Center, Allergology, Hospital Universitario Príncipe de Asturias, Universität Regensburg (UR), Research Laboratory, Carlos Hava Hospital, Department of Internal Diseases, Geriatrics and Allergology, University of Medicine, Allergy Unit, Azienda Ospedaliera Universitaria Integrata, Lung Function Unit-University of Rome, Department of Dermatology, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Respiratory Epidemiology and Public Health, Imperial College London-Royal Brompton Hospital-National Heart and Lung Institute [UK], Center of Allergy & Environment (CK-CARE, ZAUM), Helmholtz Zentrum München = German Research Center for Environmental Health, Vilnius University [Vilnius]-Faculty of Medicine, Section of Allergy and Clinical Immunology, Imperial College London-Faculty of Medicine-Royal Brompton Hospital, Division of ENT diseases, Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]-Department of Clinical Science, Intervention and Technology, Department of Child and Adolescent Medicine, University Hospital of Geneva-Medical School of the University of Geneva, Department of Biology, Faculty of Science-Uludağ Üniversitesi = Uludag University, Chair and Department of Pediatrics, Uniwersytet Jagielloński w Krakowie = Jagiellonian University (UJ), Department of Otorhinolaryngology, Head and Neck Surgery, Eskisehir Osmangazi University, Serviço de Imunoalergologia, Centro Hospitalar São João EPE, ErasmusMC, Department of Medical Sciences 'M. Aresu', University of Cagliari, Allergologia ed Immunologia Clinica, Careggi Hospital, Pédiatre A, CHU Clermont-Ferrand, UMH University, Hospital Clínico San Carlos, Universidad de Navarra, Guy's and St Thomas' Hospital [London], Royal Free Hospital [London, UK], Universität Ulm - Ulm University [Ulm, Allemagne], Ghent University Hospital, Polish Mother’s Memorial Hospital Research Institute [Lodz] (ICZMP), Klinik für Kinder und Jugendmedizin, St. Josef Hospital Ruhr University, Aarhus University Hospital, Medizinische Universität Wien = Medical University of Vienna, Institute of Molecular Biology, Oslo University Hospital [Oslo], Pediatric Allergy and Asthma Unit, Ihsan Dogramaci Children's Hospital-Hacettepe University School of Medicine, Allergie- & Asthma-Zentrum Berlin Westend, Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Department of Immunology, Rheumatology and Allergy, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Hochgebirgsklinik, Davos-Wolfgang, Skin and Allergy Hospital, King‘s College London, Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), University of Oradea, Center for Molecular Allergology, IDI-IRCCS, Unit of Pediatric allergy and Pneumology, Children's Hospital La Fe, Manchester Interdisciplinary Biocentre, Department of Allergology and Clinical Immunology, Mother Theresa School of Medicine, German Red Cross Hospital Westend, Centre for Allergy Research at Karolinska Institutet, Swiss Institute of Allergy and Asthma Research (SIAF), Allergy and Immunology Unit, Fondazione 'Salvatore Maugeri', University of Ferrara at St. Anna Hospital, Università degli Studi di Ferrara = University of Ferrara (UniFE), Internal Medicine Pad Maragliano, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Dietetics and Nutritional Science Dept, Harokopio University, Hospital La Paz Institute for Health Research, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), School of Life Sciences, University of Northumbria at Newcastle [United Kingdom], Hospital Divino Espirito Santo de Ponta Delgada, ENT Department, University Hospital Split, Hospital Civil, Nr. 101 - Odilija Rudzeviciene, Vilnius University [Vilnius], Ludwig-Maximilians-Universität München (LMU), Center of Allergy & Immunology, Complesso Integrato Columbus, Department of Pediatric Allergy, Hacettepe University = Hacettepe Üniversitesi, Immunoallergology Department, Universidade de Coimbra [Coimbra], Rimini Infermi Hospital, Greifswald University Hospital, Klinikum rechts der Isar der TU München, ZAUM, Clinic for Rheumatology and Clinical Immunology/Allergology, University Hospital of Bern, University of Edinburgh, Azienda Ospedaliero-Universitaria, Institute of Technology, University of Tartu, Department of Microbiology and Immunology, Catholic University of Leuven-Catholic University Hospitals-Clinical Immunology, Occupational Medicine, Università degli Studi di Perugia = University of Perugia (UNIPG)-Terni Hospital, Critical Care Medicine Department, National Institutes of Health - NIH, Division of Immunology and Allergy [Lausanne, Suisse], Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Department of Experimental Dermatology and Cosmetology, University of Amsterdam [Amsterdam] (UvA), Medical University Graz, Department of ENT and Pediatrics, Department of Otorhinolaryngology, Finnish Institute of Occupational Health, Allergy Research Centre, The David Hide Asthma, SpR, St James's hospital, University of Genoa (UNIGE), Children's Hospital-Geneva University Hospital (HUG), Università degli studi di Torino (UNITO), Wroclaw Medical University, Universita degli Studi di Padova, Università degli studi di Napoli Federico II-Università degli Studi di Salerno (UNISA), Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI)-DENOTHE Center, Helmholtz-Zentrum München (HZM), ROyal Free Hospital, Royal Free Hospital, Institute of Epidemiology and Medical Biometry, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Tartu University, Università degli Studi di Perugia (UNIPG)-Terni Hospital, BMC, Ed., Çocuk Sağlığı ve Hastalıkları, Eigenmann, Philippe, Caubet, Jean-Christoph Roger J-P, Ear, Nose and Throat, AII - Amsterdam institute for Infection and Immunity, Paediatric Pulmonology, and Other Research
- Subjects
Pulmonary and Respiratory Medicine ,allergic diseases ,medicine.medical_specialty ,Pediatrics ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,Allergy ,media_common.quotation_subject ,Immunology ,Translational research ,Disease ,research funding ,03 medical and health sciences ,0302 clinical medicine ,Disease registry ,Excellence ,Position Article and Guidelines ,medicine ,Immunology and Allergy ,Research needs ,ddc:610 ,Intensive care medicine ,030304 developmental biology ,media_common ,0303 health sciences ,ddc:618 ,business.industry ,Allergic diseases ,Public health ,RC581-607 ,allergy ,C600 ,Biobank ,3. Good health ,research needs ,Europe ,Policy ,Research funding ,030228 respiratory system ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Position paper ,Professional association ,Immunologic diseases. Allergy ,business ,policy - Abstract
In less than half a century, allergy, originally perceived as a rare disease, has become a major public health threat, today affecting the lives of more than 60 million people in Europe, and probably close to one billion worldwide, thereby heavily impacting the budgets of public health systems. More disturbingly, its prevalence and impact are on the rise, a development that has been associated with environmental and lifestyle changes accompanying the continuous process of urbanization and globalization. Therefore, there is an urgent need to prioritize and concert research efforts in the field of allergy, in order to achieve sustainable results on prevention, diagnosis and treatment of this most prevalent chronic disease of the 21st century.The European Academy of Allergy and Clinical Immunology (EAACI) is the leading professional organization in the field of allergy, promoting excellence in clinical care, education, training and basic and translational research, all with the ultimate goal of improving the health of allergic patients. The European Federation of Allergy and Airways Diseases Patients' Associations (EFA) is a non-profit network of allergy, asthma and Chronic Obstructive Pulmonary Disorder (COPD) patients' organizations. In support of their missions, the present EAACI Position Paper, in collaboration with EFA, highlights the most important research needs in the field of allergy to serve as key recommendations for future research funding at the national and European levels.Although allergies may involve almost every organ of the body and an array of diverse external factors act as triggers, there are several common themes that need to be prioritized in research efforts. As in many other chronic diseases, effective prevention, curative treatment and accurate, rapid diagnosis represent major unmet needs. Detailed phenotyping/endotyping stands out as widely required in order to arrange or re-categorize clinical syndromes into more coherent, uniform and treatment-responsive groups. Research efforts to unveil the basic pathophysiologic pathways and mechanisms, thus leading to the comprehension and resolution of the pathophysiologic complexity of allergies will allow for the design of novel patient-oriented diagnostic and treatment protocols. Several allergic diseases require well-controlled epidemiological description and surveillance, using disease registries, pharmacoeconomic evaluation, as well as large biobanks. Additionally, there is a need for extensive studies to bring promising new biotechnological innovations, such as biological agents, vaccines of modified allergen molecules and engineered components for allergy diagnosis, closer to clinical practice. Finally, particular attention should be paid to the difficult-to-manage, precarious and costly severe disease forms and/or exacerbations. Nonetheless, currently arising treatments, mainly in the fields of immunotherapy and biologicals, hold great promise for targeted and causal management of allergic conditions. Active involvement of all stakeholders, including Patient Organizations and policy makers are necessary to achieve the aims emphasized herein. ispartof: Clinical and Translational Allergy vol:2 issue:1 pages:21- ispartof: location:England status: published
- Published
- 2012
47. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice
- Author
-
Mertes, P. M., Malinovsky, J. M., Jouffroy, L., Aberer, W., Ingrid Terreehorst, Brockow, K., Demoly, P., Other Research, Paediatric Pulmonology, Ear, Nose and Throat, and Faculteit der Geneeskunde
- Abstract
These guidelines represent the updated consensus of experts in the field of immediate hypersensitivity reactions occurring during anesthesia. They provide a series of valid, widely accepted, effective, and easily teachable guidelines that are the fruit of current knowledge, research, and experience. The guidelines are based on the findings of international scientific research and have been implemented in France under the auspices of the French Society for Anaesthesia and Intensive Care (Societe Francaise d'Anesthesie et de Reanimation [SFAR]) and the French Society of Allergology (Societe Francaise d'Allergologie [SFA]). The members of the European Network for Drug Allergy approved the guidelines. This paper presents the most relevant clinical implications of the guidelines
- Published
- 2011
48. [Angio-oedema and urticaria as side effects of frequently used drugs]
- Author
-
Juliette J, Hoefnagel, Kristel, Wehmeijer, Ingrid, Terreehorst, and Esther J, van Zuuren
- Subjects
Adult ,Drug Hypersensitivity ,Male ,Urticaria ,Anti-Inflammatory Agents, Non-Steroidal ,Humans ,Angiotensin-Converting Enzyme Inhibitors ,Female ,Angioedema ,Middle Aged ,beta-Lactamases ,Aged - Abstract
Angio-oedema and urticaria can be symptoms of both allergic (IgE-mediated) and non-allergic drug hypersensitivity reactions. Non-allergic drug reactions, that may have a similar clinical presentation as allergic drug reactions, are not caused by an IgE-mediated immune mechanism. Because of unfamiliarity with non-allergic drug reactions and the unclear time course between drug use and reactions, the relationship with the responsible drug is often not recognized, leading to unnecessary patient risks. In the present article three patients with angio-oedema and urticaria as side effects of frequently used drugs (ACE-inhibitors, NSAIDs and betalactams) are presented and discussed. Patient A was a 69-year-old man with ACE-inhibitor induced angio-oedema. Patient B was a 40-year-old woman with urticaria and angio-oedema after ingestion of a NSAID caused by a non-allergic drug reaction. Patient C was a 54-year-old woman who developed an anaphylactic shock because of a type I allergy to betalactams.
- Published
- 2010
49. [Ambrosia in the Netherlands. Allergic sensitisation and the distribution of plants and pollen]
- Author
-
Letty A, de Weger, Abraham C, van der Linden, Ingrid, Terreehorst, Wout J, van der Slikke, Arnold J H, van Vliet, and Pieter S, Hiemstra
- Subjects
Humans ,Pollen ,Rhinitis, Allergic, Seasonal ,Public Health ,Allergens ,Ambrosia ,Immunoglobulin E ,Netherlands - Published
- 2009
50. Anaphylaxis after consuming soy products in patients with birch pollinosis
- Author
-
J. H. Akkerdaas, R. A. Tupker, Ingrid Terreehorst, E.J. van Zuuren, and Pieter S. Hiemstra
- Subjects
biology ,business.industry ,Immunology ,Immunoglobulin E ,medicine.disease_cause ,medicine.disease ,Pollen ,biology.protein ,medicine ,Immunology and Allergy ,In patient ,Food science ,business ,Anaphylaxis - Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.